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Iv\

Inhibitory effect of dioctyl sodium sulfosuccinate (DOSS), a
medicinal surfactant, was studied on the proteinase activity of
trypsin and pepsin in vitro, using both natural and synthetic sub
strates.
The inhibitory effect of DOSS was studied under various
reaction conditions such as inhibitor concentration, enzyme con
centration, substrate concentration, pH and various mixing orders
of the components. Mechanisms of inhibition were delineated using
initial velocity studies and various garphical techniques.
Studies with trypsin both at pH 6.4 and pH 7.6, indicate that in
the presence of a natural substrate, substrate-inhibitor interac
tion involving substrate depletion is the major mechanism of inhi
bition.
Some direct enzyme inhibition may also occur.
In the
presence of a synthetic substrate, a similar inhibitory mechanism
seems to exist at pH 8.2, but at pH 6.4 a true competitive enzyme
inhibition forms the only mechanism.
Results of the dialysis
studies indicate that DOSS interacts both with the enzyme and the
substrate in an irreversible fashion.
Using hemoglobin, as the natural substrate, mechanistic studies
with pepsin revealed that the antipeptic activity of DOSS is due
to a major mechanism of substrate-inhibitor interaction.
With the
synthetic substrate, however, the inhibition of pepsin was found
to be due to competition between the substrate and the inhibitor
molecules for the enzyme.
Possible therapeutic significance of the inhibitory studies was
discussed.
A possible use of dioctyl sodium sulfosuccinate in the
medical treatment of pancreatitis and peptic ulcers was suggested.
Certain implications of the study were also discussed from the
points of view of biopharmaceutics and drug interactions.
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CHAPTER I

INTRODUCTION

Body proteinases are molecules of relatively small size and of
compact, nearly spherical structure-

They generally are among the

simple enzymes which are devoid of allosteric regulatory mechanisms for
controlling the enzymatic activity.
vator ions.

Most of them do not need any acti

With the exception of pepsin, most proteinases can with

stand rather extreme conditions of pH and temperature.

Reversible

dénaturation is very common among proteolytic enzymes and one of the
best investigated examples is the reversible dénaturation of trypsin
(6 ).

Proteolytic enzymes are destructive agents which could rapidly

destroy living cells including those which manufacture them.

Therefore,

protection against the unwanted effects of these enzymes has to be pro
vided.

This is accomplished in a number of ways:

(1) Manufacture of

the enzymes as inactive precursors, the so called zymogens,

(2) The

storage of the enzymes in zymogen granules whose membrane are resistant
to proteolysis.

(3) Presence of powerful and specific natural inhibi

tors of the active enzymes.

Often more than one mechanism is available

in the living organism.
Although there is no unique way of classifying these enzymes,
various characteristics of these enzymes have formed the basis of dif
ferent types of classifications

(17, 46, 75).

Trypsin is an endopepti-

dase with a serine residue included in the active center and belongs to
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the enzymes of animal origin.

Pepsin is also an endopeptidase of animal

origin but this enzyme unlike trypsin, belongs to the acid proteinases.
Proteolytic enzymes have many similarities in their primary
structure in that all of them can be basically compared to the structure
of chymotrypsinogen (45).

Another important structural feature among

these enzymes is the position of disulfide bridges, which results in a
similar gross disposition of the polypeptide chains of these enzymes.
Reactions catalyzed by proteolytic enzymes can be divided into
five categories as follows:

(1) Hydrolysis of peptide bonds.

ysis of amide of amino acids.
dation reactions.

(4)

(2) Hydrol

(3) Peptide bond synthesis and transpepti-

Hydrolysis of esters of amino acids.

(5) Ex

change of oxygen between water and the carboxyl group of amino acids.
From all five of these types of reactions, hydrolysis of the peptide
bond is the natural function of proteinases.

Trypsin is maximally

active at pH 7 and is rather specific for cleaving all peptide linkages
in the substrate protein whose carbonyl groups are contributed by argi
nine and lysine.

Pepsin initiates hydrolysis of native proteins by

cleaving peptide linkages in which the amino function is contributed by
aromatic and acidic amino acids.
The theories on the role of proteolytic enzymes in physiological
and pathological states in man and animals have been the topic of
great controversy during the recent years.

The old belief that these

enzymes catalyze protein synthesis no longer exists, yet it would be
equally unjustified to restrict the role of body proteinases to a few
processes like cleavage of food proteins, mobilization of tissue pro
teins, and protein degradation usually associated with physiological
wear and various traumas.

In fact, it is now evident that these enzymes
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play a causative or adjunctive role in a number of disease processes
such as inflammation, thromboembolic disorders, complement dependent
immune reactions, peptic and duodenal ulcers, pancreatitis and even in
some of the syndromes of malignant carcinomas (25).

Trypsin and kallik-

rein which are present in the body tissues and fluids are capable of
releasing

pharmacologically active plasma kinins (94).

These proteo

lytic enzymes play an indirect but significant role in some of the im
portant conditions like hypertension, shock, certain pains, changed
capillary permeability, edema, and leucocyte migration.

Much evidence

is available to support the central role of trypsin in the pathogenesis
of pancreatitis (25, 38, 108).

Direct as well as indirect evidences

also indicate that through some yet unknown mechanism, the normal resis
tance of the gastric mucosa to acid and pepsin is compromised in all
peptic ulcers (50).

Therefore, the role of pepsin in the pathogenesis

of peptic ulcres seems significant ( 67,

88, 97, 106 ).

In the light of

this knowledge, the proteinase inhibitors, both synthetic and natural,
have gained new theoretical and practical importance (108).

Recently

attempts have been made to synthesize some active site-oriented inhibi
tors as well as to improve their inhibitory activity (11, 40, 75).
Also, it is reported that proteolytic enzymes are inhibited by agents
such as sodium dodecyl sulfate and some sulfated polysaccharides (2 ,
83).
Dioctyl sodium sulfosuccinate is an anionic surfactant that is
widely used medicinally as a fecal softener (52).

The effect of this

surfactant on drug absorption through membranes of varying complexities
has already been reported (41, 59, 71).

This agent strongly suppresses

the ulcer formation in restrained rats when given intraduodenally (69).
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Absorption of dioctylsodium sulfosuccinate into the systemic circula
tion has been reported (28).

These findings and the similarity of the

chemical nature of this medicinal surfactant to some proteolytic inhibi
tors such as sodium dodecyl sulfate and sulfated polysaccharides and
protein macroanions

(96, 104) led to this investigation dealing with

the inhibitory effect of dioctyl sodium sulfosuccinate on trypsin and
pepsin in vitro.

Such an in vitro investigation was deemed to be of

interest because of the following reasons:
1.

Dioctylsodium sulfosuccinate might play an important role in the
medical treatment of pancreatitis and peptic ulcers through its
inhibitory effects against trypsin and pepsin respectively in vivo.

2.

The recent practice of polypharmacy, i.e., prescribing drug combin
ations has let to enormously increasing drug interactions (55, 64
103).

The simultaneous use of certain digestive enzymes like tryp

sin and chyraotrypsin along with dioctyl sodium sulfosuccinate may
represent such an interaction.

An in vitro inhibition study would

help in predicting and/or explaining such drug-drug interactions.
3.

The pharmacological action of many prodrugs is dependent on the
action of proteinases of the gastro intestinal tract (98).

There

fore, inhibition of these proteolytic enzymes by dioctyl sodium
sulfosuccinate may be of significant therapeutic significance.
4.

The studies of enzyme inhibitions also provide valuable information
about the substrate specificity, the nature of the functional groups
at the active site of the enzyme, mechanism of enzyme action and the
participation of certain functional groups in maintaining the
specific conformation of the enzyme molecule (6 6 ).
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5.

Inhibition studies provide important guidelines for the design of
potent specific inhibitors which may prove useful therapeutic agents.
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CHAPTER II

SURVEY OF LITERATURE

Role of Body Proteinases in Physiology and Disease
Proteolytic enzymes in protein digestion.

Most historical and

one of the important physiologic functions of proteinases has been asso
ciated with the digestion of food proteins in the gastrointestinal tract
(73, 112).

Protein digestion begins in the stomach where pepsin is

liberated from the pepsinogen by the action of gastric hydrochloric acid.
Pepsinogen is secreted by the chief or peptic cells of the stomach.
Human gastric mucosa has been shown (95 ) to contain three chromatographically distinct pepsinogens which produce three different pepsins with
slightly different properties

(Pepsins I, II and III).

pepsin digestion are polypeptides of various sizes.
liquifies gelatin is also found in the stomach.

Products of

A gelitinase that

Rennin is another

enzyme of stomach responsible for milk clotting and is only found in
young animals.

Because pepsins have a pH optimum of 1.6 - 3.2, their

action is terminated when the gastric contents are mixed with the alka
line pancreatic juice in the duodenum.
is about 6.5.

The pH of the duodenal contents

In the small intestine, small polypeptides and dipeptides

are formed by the action of the powerful protein splitting enzymes,
trypsin and chymotrypsin which are major enzymes of the pancreatic juice
secreated by the exocrine portions of the pancreas.

Trypsin and chymo

trypsin are produced as their inactive zymogens trypsinogen and several
related chymotrypsinogens.

Trypsinogen is converted to active trypsin

6
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by enterokinase, an enzyme secreted by the duodenal mucosa.

Enterokinase

also seems to convert procarboxypeptidases of pancreatic juice to active
carboxypeptidases.

This enzyme contains about 41% polysaccharides that

prevent it from being digested itself before it can exert its effect.
Trypsin converts chymotrypsinogens into chymotrypsins.

An elastase that

hydrolyses fibrous proteins and a collagenase are also present in pan
creatic juice.

The pancreatic carboxypeptidases and the amino peptidases

and dipeptidases of intestinal mucosa split polypeptide fragments into
free amino acids.

Amino acids may be liberated in the intestinal lumen

or at the cell surfaces that line the luminal border of the mucosal
cells (58, 77).

Dipeptidases activities are low in the proximal part of

the duodenum but increase rapidly in its distal part to reach maximum
value in the jejunum and ileum (6 8 ).

The rates of digestion of the

dietary proteins vary rather widely, depending upon stomach emptying
time, the nature of the protein, and the other food constituents ingested.
Various enzymes involved in digestion are present in relatively large
amounts, therefore hydrolysis per se cannot be considered as a rate
limiting factor for absorption of amino acids

(18).

Thus conversion of

many food proteins, collagen, nucleoproteins and certain endogenous pro
teins to the free amino acids is a prominent physiological function of
the various proteolytic enzymes of gastric, pancreatic and intestinal
secretions.
Proteolytic enzymes in blood coagulation.

Proteolytic enzymes

also play important roles in the process of blood coagulation.

For

over a century blood clotting has been thought to involve enzymatic
action (84).

While the classical theory of coagulation considered the

clotting factors to be enzymes circulating in an inactive or zymogen
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8
form ( 8 4 ) some earlier investigators believed coagulation was the result
of a physical combination or stochiometric reaction of the constituents
C 84,

92 ).

Both theories turned out to be true, when a dozen separate

plasma proteins or clotting factor activities were discovered to be in
volved in the process of coagulation.

These factors are:

I, fibrinogen;

II, prothrombin; III, thromboplastin; IV, calcium; V, proaccelarin; VII,
proconvertin; VIII, antihaemophilic factor (AHF); IX, plasma thrombo
plastin component (PTC) or Christmas factor; X, Stuart power factor; XI,
plasma thromboplastin antecedent (PTA); and XII, Hageman factor (84,
113).

Factor la is covalently bonded or urea insoluble fibrin; Xllla is

the activated form of the factor XIII

(figrinoligase), fibrin stabiliz

ing factor and PL is Platelet phospholipid.
The coagulation of blood results both from enzymatic and stochio
metric reactions
to enzymes

(56) and involves the activation of perhaps five zymogens

(Xlla, IXa, Xa, Ila, and Xllla) and the formation by physical

combination of three complexes

(34).

The fundamental reaction in the

clotting of blood is conversion of the soluble plasma protein fibrinogen
to fibrin.

The fibrin molecules polymerise to form a loose mesh of in

soluble interlacing strands and this polymer is converted by the formation
of covalent cross linkages to a dense, tight aggregate.

This latter re

action is catalyzed by factor XIII, the fibrin stabilizing factor or
fibrinoligase, an important proteolytic enzyme.

The clotting mechanism

responsible for the formation of fibrin involves a complex series of
reactions (Fig.

1).

In this complex sequence the conversion of fibrino

gen to fibrin is catalyzed by thrombin, another proteolytic enzyme.
Thrombin is formed from its circulating precursor prothrombin, by the
action of activated factor X.

Factor X can be activated by reactions
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Extrinsic System

Intrinsic System

III

-> Xlla

XII

XI
VII

IXa

IX
VIII

PL
---- > Xa

II

Ila

la (Soluble)
Xllla
la (Insoluble)

Figure 1 .--Diagrammatic Summary of the Clotting mechanism.
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that proceed along either of two pathways, an intrinsic and an extrinsic
pathway as shown in Figure 1 .

The complicated and repetitive pattern of

coagulation acts as a biologic amplifier in which a several fold gain of
activity is achieved with each stage (70).

Some product of coagulation

accelerates the development of thrombin and fibrin, hence blood clot
ting can be termed an autocatalytic reaction.

It is this chain reac

tion pattern and explosive characteristic of blood coagulation that
contributes to the growth of a hemostatic plug or the propagation of a
thrombus

(78).
In addition to their role in blood clotting certain proteinases

also seem to participate in the anticlotting mechanisms of blood.

Fib

rinolytic system of the body is such a mechanism that limits clotting.
The active component of this system is a proteolytic enzyme, plasmin or
fibrinolysin.

This enzyme not only cleaves fibrin but also attacks

factor V, factor VIII and fibrinogen, with the liberation of substances
that inhibit thrombin.
Proteolytic enzymes in pancreatitis.

Pancreatitis can be re

garded as a chemical autolytic process the pathogenesis of which is well
documented from postmortem, operative and experimental studies (15).
The exact mechanism of the pathological process has yet to be estab
lished.

However, evidence is available supporting the central role of

certain body proteinases in the pathogenesis of the disease.

It has

been reported (25) that pancreatic duct obstruction coupled with intrapancreatic conversion of trypsinogen to trypsin is one of the most
important mechanisms in the production of pancreatitis.
was challenged by Beck and coworkers

This hypothesis

(14) who demonstrated that no free

trypsin was found in hemorrhagic or necrotizing pancreatitis in dogs.
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However, this can easily be accounted by the presence of pancreatic and
serum inhibitors.

The recent reports

trypsin inhibitors such as trasylol

(74) on the usefulness of specific

(trypsin inhibitor from bovine

organ) have further strengthened the case for the importance of trypsin
in pancreatitis.
Furthermore, some workers (22, 23, 43, 80-82) have reported
higher levels of plasma trypsin in cancer of pancreas and acute pan
creatitis as compared to those in the normal subjects.
contradicting reports

Nevertheless,

( 9, 10, 25 ) also prevail claiming no differences

between the plasma trypsin levels of patients with pancreatitis and
those of normal individuals.

These controversial claims may be ex

plained due to the fact that different groups of workers used different
synthetic substrates.

Lack of a reproducible assay which is specific

for trypsin in human plasma or serum may obviously be another reason.
Another mechanism through which trypsin may cause pancreatitis
may be due to its ability to liberate certain vasodepressor kinins from
serum globulin.

Evidence has been obtained that trypsin is enhanced in

its ability to produce pancreatitis by incubation with serum (1).

The

ability of bradykinin to cause hypotension, pain, vasodilatation, in
creased vascular permeability, smooth muscle stimulation, leucocyte
migration, and leucocyte accumulation also suggests the possibility that
bradykinin may play a part in a disease process such as acute haemorrhagic pancreatitis, characterised by hypotension, pain, haemoconcentration, dynamic fluid shifts, leucocytosis, edema and leucocyte infiltra
tion of the gland ( 94 ) •

This hypothesis is further supported by the

fact that pancreas contains large quantities of trypsinogen and kallikreinogen, both of which in active form, are capable of releasing
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12
bradykinin from its inactive precursor, bradykininogen.

Bradykininogen,

as a normal pseudoglobulin of plasma, lymph and interstitial fluid is
readily available to the pancreas.
Two important systems related to the proteolytic release of
pharmacologically active kinins in the body have recently been described
( 76, 85 ).

These are renin-angiotensin system and the kinin system.

Renin is the proteinase involved in the renin system and the kinin sys
tem involves certain kininogenases, and kininases as the active enzymes.
Plasmin and trypsin are also able to release bradykinin from their
kininogen substrates.

The particular proteolytic enzymes involved may

be from a glandular source or of plasma.
Acute pancreatitis can also be related to the mechanism of acti
vation of pancreatic proteinases

(30).

Studies on the enzyme mechanisms

involved suggest that during activation of pancreatic proteinases,
enterokinase converts trypsinogen into trypsin.

Trypsin then reacts

with trypsin inhibitor to form a trypsin-trypsin inhibitor complex.
After interaction with bile, trypsin inhibitor decreases and free tryp
sin appears.

Free trypsin then converts inactive zymogens of pancreas

into active proteases.

Trypsin inhibitor is thought normally to protect

the pancreas against this premature activation within the gland.
trypsin inhibitor becomes depleted in a damaged pancreas

When

(ischemia) it

is postulated that the emerging proteinases digest the parenchyma and
acute hemorrhagic pancreatitis results.
Trypsin also converts prophospholipase A into the active enzyme,
phospholipase A.
lysolecithin.

This enzyme splits a fatty acid off lecithin forming

Lysolecithin damages cell membranes.

The cause of acute

pancreatitis may be activation of phospholipase A in the pancreatic
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ducts, with the formation of lysolecithin from lecithin which is a
normal constituent of bile.

This may cause disruption of pancreatic

tissues and necrosis of surrounding fat (38).
Proteolytic enzymes in peptic ulcers.

Peptic ulcers can be de

fined as acute or chronic ulcerations of the digestive tract, occuring
in an area accessible to gastric secretions.

It is a common disorder of

gastro intestinal tract that even today continues to be an incompletely
understood disease.

Although very little is known about the definite

etiology of the disease, yet an interrelationship of a number of mucosal
defensive factors and aggresive factors seems to determine an individ
ual's susceptibility to ulcers

(50, 93).

Nevertheless it is important

to note that none of these factors itself, has been shown to exert a
strong enough effect to result in the large variations seen among various
populations in the incidence of peptic ulcers (50).

Whatever may be the

causative factors, it has now been unequivocally established that through
some unknown mechanism, the normal resistance of the gastric mucosa to
acid and pepsin is compromised in all peptic ulcers (50).

Some direct

experimental evidence is available indicating the importance of pepsin
in the pathogenesis of the disease ( 67,

8 8 , 97, 106 ).

In humans, the

role of pepsin in gastroduodenal ulceration has been indirectly evidenced
by the antiulcer activity shown by some macroanions which also inhibit
peptic hydrolysis in vitro ( 96, 104).

Pathophysiology of peptic ulcers

may involve abnormalities of acid-pepsin secretion, presence of acidpepsin at unusual sites or predisposition of the mucosa to ulceration
(51).

Such pathophysiological abnormalities may be a consequence of

various physiological, anatomical, epidemiological, genetic or even
environmental factors (38, 51).
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Weiss and Serfontein (110) have recently indicated some of the
qualitative and quantitative biochemical differences between the ulcer
ated tissues and the surrounding normal tissues.

Compounds like hexo-

samines, hyaluronic acid, mucopolysaccharides and the glycoproteins seem
to be present at higher concentrations and in more reactive forms at the
ulcerated tissue than at the normal surrounding cells.
Proteinases may play an important role in the inflammatory pro
cess by releasing vasoactive peptides.
complement

From the fifth component of

(C5 ) they also release a potent chemotactic factor €5%) that

can attract macrophages and polymorphonuclear leukocytes to the site of
inflammation.

Macrophage proteinase may therefore be an important medi

ator of parts of the chronic inflammatory process
Miscellaneous.

(72).

In addition to their presence in the oxyntic

glands and the pyloric glands of the stomach, the pepsin zymogens are
also reported to be present in the proximal deuodenum, in seminal fluid
(of seminal viscicles origin), in amniotic fluid (probably of fetal
origin) and in blood and urine

(96).

Pepsin determination either as

uropepsin or plasma pepsin (42, 79) has been a standard clinical prac
tice.
anemia.

Uropepsin values are high in duodenal ulcers and low in pernicious
Uropepsin is decreased in cirrhosis, Addison's disease, panhy

popituitarism, and myxedema (25).

Blood pepsin seems to reflect the

total secretory potential of the stomach (102) yet in superficial gas
tritis with achlorhydria blood pepsin may rise due to regurgitation from
glands blocked with inflammatory cells.

The blood levels of pepsin may

decrease if gastric atrophy predominates.
The use of chymotrypsin in opthalmology for extracting cataract
and in certain inflammatory diseases has been reported (25).
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the role of trypsin in chemotherapy is controversial, the use of this
proteolytic enzyme in pulmonary alveolar proteinosis, in promoting heal
ing of opisitomies and certain inflammatory processes has been indicated
(25).

Small amounts of trypsin have also been reported to accelerate

blood clotting (35).
Elastase is another pancreatic proteolytic enzyme which can con
vert prothrombin to thrombin, thereby shortening the clotting time but
it has no action on fibrinogen.

Elastase has not been determined in

serum but it has been claimed by certain workers that this enzyme plays
a central role in atherosclerosis (12, 25).

However, any role for this

enzyme in human physiology and disease needs more investigations.
Certain kallikreins in the human plasma and urine have been reported
which differ from the pancreatic kallikrein in their immunologic proper
ties.

Besides their role in the pathogenesis of pancreatitis and certain

other inflammatory diseases, this enzyme has also been implicated in the
production of certain aspects of malignant carcinoid syndromes

(25).

Plasmin, leucine amino peptidase, carboxypeptidases A and B,
cathepsins and certain other proteinases of human body have been re
viewed by Colman in relation to their role in physiology, pathology and
therapeutics (25).

Proteinase Inhibitors
Enzyme inhibition is an extensively studied field of enzymology.
An important aspect of this work is concerned with the identification of
active site residues and structure and function of the active center of
enzyme.

Enzyme-inhibitor interactions are also important from the point

of view of kinetics of the reaction.

The practical importance of these

studies lies with their utility in the control of certain diseases.
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Various inhibitors of proteolytic enzymes can be classified into
several categories according to their mode of action:
irreversibly destroying the enzyme.
bitors.

C3)

(2) Noncompetitive reversible inhi

Competitive reversible inhibitors.

ed irreversible inhibitors.

(1) Inhibitors

(4) Active site direct

(5) Specific protein inhibitors.

These proteolytic inhibitors, in particular the specific protein
inhibitors of both synthetic and natural origin have proved very useful
in certain diseases.

Pancreatitis and peptic ulcers are two major dis

orders among such diseases in which trypsin and pepsin respectively have
been shown to play a central role.

Therefore, important inhibitors of

these two proteolytic enzymes are discussed as follows.
Trypsin inhibitors.

A reversible competitive trypsin inhibitor

from the extract of Ascaris lumbricoides has been isolated by Pudles
et al (89).

One microgram of the inhibitor has been found to give 100%

inhibition of 0.5 ug of trypsin and the dissociation constant of the
complex is 3xl0“^m.

This inhibitor can also inhibit kallikrein.

Along

with trypsin inhibitor, in the ascaris extract, a pepsin inhibitor has
also been reported.

The presence of these inhibitors in Ascarides is

thought to be a defense mechanism against the proteinases of the host
organism.
Kunitz isolated a trypsin inhibitor form bovine pancreas (63).
Pancreatic inhibitor is characterized by a high stability to acids, to
heat and to pepsin.

The stability decreases with increasing alkalinity.

The isoelectric point is at pH 10 or 10.5.

The inhibitor seems to form

salts at acid pH values and is resistant to proteolytic degradation.
This inhibitor has also been referred to as bovine trypsin kallikrein
inhibitor, polyvalent inhibitor, Kunitz inhibitor and basic pancreatic
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trypsin inhibitor.

It is commercially available in highly purified form

under the names Iniprol and Trasylol.

Another trypsin inhibitor has

been found in human, bovine and pig colostrum in an activity ratio of
1:10:67 (108).

One milliliter of pig colostrum gives 100% inactivation

of 2 mg of trypsin.

One milliliter of cows' milk gives 50% inhibition

of the proteolytic activity of 500 pg of trypsin.

The maximum inhibitor

concentration in human milk is reached between the third and fifth day
post partum and corresponds to the inhibition of 50-70 yg of trypsin per
milliliter of milk.

The inhibitor is stable to acid and heat.

an isoelectric point at pH 4.2.

It has

A trypsin inhibiting component has been

detected in the placenta (108) and in the amniotic fluid (108), as well
as in the heart,

lungs, and brain of various species (21, 108).

Human blood serum has been reported to contain two trypsin inhi
bitors (16, 20, 24, 29, 32, 108).

These

inhibitors

to be present in the aj and U 2 globulin fractions.

have been located
The inhibitor from

the a% fraction is an inhomogenous inhibitor which is unstable to heat
and acids.
acid.

It is not dializable and is precipitated by trichloroacetic

Its isoelectric point is pH 4.0.

The second trypsin inhibitor

which belongs to «2 globulin fraction, is characterized by a strong and
instantaneous inhibiting capacity for plasmin.

This inhibitor, there

fore, is also known as a 2-macroglobulin plasmin inhibitor.
tion is stochiometric and reversible.

The inhibi

This inhibitor is relatively

stable to heat and can also inhibit chymotrypsin.

One milligram of

inhibitor inhibits 17-40 pg of trypsin.
Haverback

( 47-48) found that human pancreatic juice obtained by

drainage contained an inhibitor for trypsin and chymotrypsin which is
soluble in trichloroacetic acid and is stable to trypsin and chymotrypsin,
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In duodenal secretion the trypsin inhibitor of pancreatic juice is de
stroyed in the trypsin-inhibitor complex by excess trypsin, or chymo
trypsin.

The inhibitor level in the pancreatic juice can fall to mini

mal level in experimental pancreatitis.
in chronic pancreatitis the ratio of the inhibitor to the trypsin
in the duodenal secretion is reduced from 4.1 to 1.3 by a high protein
diet

(19).

This inhibitor is different from the Kunitz's pancreatic

inhibitor in structure and properties.
A specific trypsin inhibitor from the extracts of ovarian tumors
has been reported (19).

The inhibition of trypsin is more pronounced

for the extracts of benign tumors than those of malignant ones.

The

nature of the inhibitor is yet poorly characterized.
Trypsin inhibitors from various bovine organs like parotid
glands, liver and lungs have also been described.

Astrup found that

human urine contains a trypsin-inhibiting component that can be separated
from urokinase by franctionation on calcium phosphate gel (7-8).
microgram of the purified inhibitor inhibits 0.83 ug of trypsin.

One
The

inhibitor shows practically no loss of activity at pH 2-3.5 after 30
minutes at 100“ C.

It is an acidic polypeptide, whose isoelectric point

is pH 2.1.
An organ sepcific and sex specific trypsin inhibitor has recently
been discovered.

This inhibitor has been found in the vesicular glands

and semen of all mammals including man (108).
polypeptide which is stable to heat and acids.

The inhibitor is a basic
This inhibitor forms 1:1

complex with trypsin and the complex formed is reversible.
A trypsin inhibitor from the submandibular and sublingular glands
has been isolated.

The inhibitor is a strongly basic polypeptide with

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

19
isoelectric points of pH 12 and 12.5 (108).

One microgram of inhibitor

inhibits 3 yg of trypsin and has maximum effect between pH 7-8.
A trypsin inhibiting principle from Clostridium-botulinum and a
trypsin inhibitor from Aspergi1lus-soyae that preferentially inhibit the
microorgnism’s own alkaline proteinase, have been described (5 4 , 108).
These inhibitors need further examination in detail.
A number of useful trypsin inhibitors have also been obtained
from various plant sources.

Soybean inhibitor is the most extensively

studied of all the natural proteinase inhibitors.

Trypsin is known to

combine with this inhibitor in a stochiometric, reversible, pH dependant
reaction (60).

It has been found to inhibit trypsin in a noncompetitive

fashion in the presence of a natural substrate.

Kinetic and thermody

namic and other biochemical studies of the interaction between this in
hibitor and trypsin have been so extensive that this inhibitor has become
a model substance for inhibitory studies of trypsin.
Sohonie isolated the trypsin inhibitor from mung beans

(100).

It has a molecular weight of 18,000, is relatively stable to heat and
it inhibits trypsin stochiometrically.

Crystalline trypsin inhibitors

have also been isolated from field beans and broad beans (37, 100-101).
Two other trypsin inhibitors of plant source have been isolated from lima
beans and garden beans respectively.

The inhibitor from the lima beans

inhibits trypsin in a molar ratio of 1:1 and has an inhibition constant
of 10"8m.
Vogel et al (108) recently found another trypsin inhibitor from
beet.

The inhibitor is precipitated by trichloroacetic acid; it is

stable to acid.
lyzed.

However, it is not stable to heat and cannot be dia-

One gram of beet root tissue has been shown to give 50% inhi

bition of about 25 ug of trypsin.
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Trypsin inhibitors have also been isolated from several grains,
e.g., whole wheat flour, cord seed, rye and wheat germ, and barley [108).
The barley inhibitor is stable at 100° C for 15 minutes at pH 4.9 and to
one hour's exposure to pH 2.1 at 35° C.

It lias equal effect on the tryp

tic digestion of casein, haemoglobin and certain synthetic substrates.
Various synthetic inhibitors of trypsin have also been described.
Some of the competitive inhibitors of this kind are compounds such as
phenyl-trans-4 amino methylcyclo hexane carboxylate, p-aminobenzamidine,
benzaraidine, benzyl e-aminocaproate hydrochloride, thionine, 4-aminomethylbenzoic acid benzyl ester, proflavin, phenylguanidine, and benzylamine (75).

N-a-tosyl-L-lysine chloromethyl ketone, ethyl-p-guanidino

benzoate, broraoacetone, p-amidino-phenacyl bromide, and p-guanidinophenacyl bromide are among the more important active site directed ir
reversible inhibitors of trypsin (75).

Recently a number of diamidino-a,

w-diphenoxyalkanes have been synthesized by Geratz et al (39- 40) which
have proved to be active site directed reversible inhibitors of trypsin
and certain other proteinases.
Pepsin inhibitors.

Pepsin is inhibited by a host of natural in

hibitors which also inhibit trypsin and certain other proteinases (108).
Most of these inhibitors have already been described as trypsin inhibi
tors.

However various synthetic inhibitors which specifically inhibit

pepsin have also been synthesized (75).

Among these, compounds such as

N-acetyl-D-phenylalanayl-L-diiodotyrosine, L-phenylalanyl-L-phenylalanine
methyl ester, and benzyloxycarbonyl-L-histidyl-L-phenylalanyl-L-phenyl
alanine inhibit pepsin competitively (75).

Although these inhibitors

represent some of the strong inhibitory agents of pepsin, their utility
in the disease of peptic ulcers has not been indicated.
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Among the therapeutically useful pepsin inhibitors are the macro
anion inhibitors and certain glycopeptides as well as sulfated polysac
charides.

Some of the more important characteristics of these inhibitors

that seem to be related to their inhibitory activity and hence their
antiulcer action, may be described as follows:

(1) These inhibitors

possess a net negative charge and the interaction of the negatively
charged inhibitor with the positively charged protein substrate results
in the inhibition of peptic hydrolysis.

(2) Of all the physical and

chemical parameters molecular size and degree of sulfation seem to be
most significant in determining the antipeptic activity of the inhibitor.
The molecule has to be a certain minimum size to show pepsin inhibitory
activity.

The inhibitory activity appears to be directly correlated with

the sulfate content of the molecule.
be to related to high sulfur content.

Antiulcerogenic activity also seems
(3) The effect of pH, order of

addition of the reactants, ratio, and nature of the interacting species
of different macroanions and substrates on the inhibition of peptic
activity have been found to be important.
B a m e s et al ( 94 ) have shown the antipeptic effect of chondriotin
sulfate, heparin, carragheen and dextran sulfate on peptic activity in
vitro.

They also studied the effect of these inhibitors on the mortality

and incidence of ulcers in pylorus ligated rats.

Equivalent amounts of

heparin, carragheen and dextran sulfate produced equivalent inhibition
of peptic activity in vitro, but dextran sulfate was more effective both
in decreasing the mortality and the incidence of ulcers.
A number of lignosulfonates have been shown to exert antipeptic
activity as well as antiulcerogenic effects (105, 107).

Inhibition of

peptic activity by carbonoxolone and glycyrrhetinic acid has been re
ported by Henman (49).
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A concentration and pH dependant inhibition of pepsin by heparin,
ribonucleic acid, chondriotin sulfate and a sulfated glycoprotein frac
tion from human gastric juice has been shown by some workers (3, 53).
Significant inhibitory effect on pepsin and a reduction of the occurence
of peptic ulcers have been reported with SN-263 (sulfated amylopectin or
depensen) and carrageenan (31).
Fogelson (36) in an uncontrolled study, treated 12 patients with
gastric ulcer with a crude preparation of gastric mucin, which can inhi
bit pepsin.
found

Calcium chondriotin sulfate and paritol C have also been

to possess some antipeptic activity.
Cook et al (26) have reported the antipeptic and antiulcerogenic

activity of a number of synthetic sulfated polysaccharides.

They also

correlated a number of physical and chemical parameters of these inhibi
tors to their inhibitory effects and the antiulcerogenic activity.
The inhibition of the peptic activity of human gastric secretion
by undegraded and degraded carrageenans of similar sulfate content has
been examined at various pH values by Anderson and Baillie (2).

These

workers also showed the protective action of carrageenans against ex
perimental ulcers in guinea pigs (4).
antagonists of pepsin.

Alkalies are among the most potent

Any base raising the pH of the gastric juice to

7 or above will inhibit most of the pepsin within a few seconds.

Sodium

dodecylsulfate has also been shown to significantly reduce the pepsin
activity within 2 hours (83).
By far the most active and specific inhibitor of pepsin is pepstatin, which is a pentapeptide with two y-NH linkages, two B-OH groups
and five branched aliphatic side chains.

It has been reported to be

nontoxic and is produced by Banyu Pharmaceutical Co. in Tokyo for the
treatment of peptic ulcers

(72).
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Antipeptic activity of sulfate glycopeptide has been recently
reported by Prino et al ( 88 ).

The glycopeptide was shown to inhibit

peptic activity of human gastric juice.

It aslo proved effective in

duodenal ulcers in man and animals when tested in vivo.
Thus, most of the macroanion pepsin inhibitors have proved to be
of significant value in peptic ulcers of animals and man.

However addi

tional well controlled clinical studies are needed to completely delin
eate the efficacy of these inhibitors in the treatment of peptic ulcers.
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CHAPTER III

OBJECTIVES OF RESEARCH

In spite of the fact that dioctyl sodium sulfosuccinate (DOSS)
is widely used in medicine as fecal softener, no report is available of
its systemic use.

Probably because until recently DOSS has been claimed

to show no absorption in the blood.

Dujovne and Shoeman have now shown

that this compound is significantly absorbed into systemic circulation
(28).

Lish (69) has shown that DOSS when administered intraduodenally

strongly suppresses the ulcer formation in restrained rats.

These find

ings and the similarity of the chemical nature of this surfactant to
some proteolytic inhibitors such as sodium dodecyl sulfate and sulfated
macroanions suggested possible inhibitory effects of DOSS against tryp
sin and pepsin.

No study dealing with the inhibitory effect of DOSS

against these enzymes has been previously reported.

Since, it has been

established that trypsin and pepsin play a central role in the patho
genesis of pancreatitis and peptic ulcers respectively, an in vitro
investigation of the inhibitory effect of DOSS against these proteolytic
enzymes was deemed necessary in order to delineate the possible use of
DOSS in pancreatitis and peptic ulcers.
The objectives of this study are the following:
1.

Determination of the nature and extent of inhibitory effect of DOSS
on trypsin and pepsin activities in vitro using both natural and
synthetic substrates.

24
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2.

To study the effect of various reaction conditions such as inhibitor
concentration, enzyme concentration, substrate concentration, pH,
and various mixing orders of the components.

3.

To delineate the inhibitory mechanisms involved in the inhibitory
action of DOSS against trypsin and pepsin through kinetic experi
ments.

4.

Projection of the results of the in vitro inhibitory studies to the
more realistic in vivo situations of disease in pancreatitis and
peptic ulcers.
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CHAPTER IV

STUDIES WITH TRYPSIN

I.

EXPERIMENTAL

Materials
The following materials were used in these studies:
Trypsin (Beef pancreas, twice crystallized, salt free, lyophilized).
Nutritional Biochemicals Corporation.
Casein (Hammersten type).
Nutritional Biochemicals, Inc.
Na-benzoy1-DL-arginine-p-nitroanilide hydrochloride (DL-BAPNA).
Schwartz/Mann, Dickinson and Company.
Dioctyl sodium sulfosuccinate (DOSS).
"Aerosol O.T. 100%", Sargent-Welch Scientific Co.
Trizma base.
Tris

(hydroxy-methyl) amino methane. Sigma Chemical Co.

Dimethyl Sulfoxide.
J. T. Baker Chemical Co.
All other chemicals used were either U.S.P. or reagent grade.

Procedures
Methods for antitryptic activity.

Two different methods for

determining antitryptic activity were used.
Method I.
were used.

Sorensen phosphate buffers

(O.IM) of various pH values

A fresh 1% casein (S) solution was prepared by suspending
26
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1.0 g of casein in 100 ml of buffer and heating the suspension in a boil
ing water bath for 15 minutes.

Enzyme (E) solutions of various concen

trations ranging between 10-50 ug per ml were prepared by first dissolv
ing 10 mg of trypsin in 10 ml of 0.001 M HCl and then diluting with the
appropriate buffers.

Various inhibitor (I) solutions were prepared by

dissolving required amounts of DOSS in the buffers, at appropriate pH.
The assay was carried out by a modification of Kunitz’s method
(61).

In this method casein is digested under standard conditions.

The undigested casein is precipitated with trichloroacetic acid, and the
amount of unprecipitated protein split products, which is a measure of
the

proteinase

range.

activity, is estimated spectrophotometerically in u. v.

All the solutions were freshly prepared and mixed at room temp

erature before incubation.

The final volume of the digestion mixture

was kept at 10 ml in all cases.
In this method two different mixing procedures were followed:
A.

Inhibitor added to enzyme before digestion.

One milliliter

of enzyme solution was pipetted into 50 ml Erlenmeyer flasks followed by
1 ml of the inhibitor solution.

Five ml of the substrate solution was

then added to each flask at 30 second intervals.

All the flasks were

incubated in a water bath metabolic shaker^ maintained at 37* C for one
hour.

Samples were shaken at 200 r.p.m. throughout the digestion period.

At the end of incubation period, 3 ml of 10% trichloroacetic acid solu
tion was added to each flask, in the same order, and allowed to stand at
room temperature for 10 minutes.

Blanks were prepared exactly in the

same way as samples except that the casein solution was added after the
addition of trichloroacetic acid.

Both samples and blanks were then

iModel G-77, New Brunswick Scientific Co., Inc., New Brunswick,
N. J.
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centrifuged at 8000 r.p.m. in a Sorvall SS-4 superspeed centrifuge^ for
20 minutes and the supernatants filtered through Whatman #2 filter papers.
The absorbance of each fiIterate was read at 280 nm against the respec
tive blank using a Spectronic-600 spectrophotometer^.

Also, controls

were run simultaneously for every inhibition experiment.

The controls

differed from the samples in having inhibitor solution replaced by equi
valent amounts of buffers.
The absorbance values were used as measures of reaction veloci
ties in all the kinetic studies.

The inhibition (i) equals

(1-ZÎ3,

where Vj and v represent digestion velocities with and without the inhi
bitor respectively.

Percentage inhibition values were calculated from

values of (i).
B.

Inhibitor added to substrate before digestion.

The procedure

for digestion was as in (A) above except that the inhibitor solution was
added to the substrate first and mixed, followed by addition of enzyme.
Method II.

In this method Na-benzoyl-DL-arginine-p-nitroanilide

hydrochloride (DL-BAPNA), was used as the synthetic substrate.

DL-BAPNA

is a chromogenic substrate of trypsin and on tryptic hydrolysis releases
p-nitroaniline which is yellow and can be estimated colorimeterically.
The procedure used was that of Erlanger et al (33) with a few modifica
tions.
Forty-three and five tenths

(43.5) milligram DL-BAPNA was dis

solved in one ml dimethyl sulfoxide and the solution was brought to
100 ml with 0.05 M tris buffer at pH 8.2 and containing 0.02 M CaCl2 *
Care was taken to dissolve all of the DL-BAPNA in dimethyl sulfoxide.

2jvan Sorvall, Inc., Norwalk, Conn.
3Analytical Instruments, Bausch § Lorab, Rochester, N. Y.
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Presence of any crystals caused precipitation on standing.

The tempera

ture of the stock solution was never allowed to fall below 25° C.
Various concentrations of enzyme and inhibitor solutions were prepared
as described in Method I except that the buffers used were 0.05 M tris
(hydroxy methyl) aminomethane buffers of various pH values.
According to the assay procedure, all the solutions were allowed
to equilibrate at 37° C for 5 minutes before mixing.

One milliliter of

enzyme solution was pipetted into each of the 50 ml Erlenmeyer flasks,
which were already brought to 37° C.
1 ml of the inhibitor solution.

This was followed by addition of

At zero time, 5 ml of the substrate

solution was added into each of the sample flasks.
and

Appropriate blanks

controls were prepared in the same manner as described in Method I.

Incubation of the samples, blanks and their respective controls was done
at 37° C for 300 seconds in a water bath metabolic shaker except for
data of Table 13, and Figure 12, in which case incubation was done for
600 seconds.

All the flasks were shaken at 100 r.p.m. throughout the

incubation period.

The reaction was stopped by adding 1 ml of 30% acetic

acid to each flask.

The final volume of the reaction mixture was kept

at 8 ml in each case.

All incubation mixtures were centrifuged and then

filtered as described in Method I.

The absorbance of the filtrates of

both samples and blanks was recorded at 410 nm against distilled water
using a Beckman ACTA G U I

Spectrophotometer.

Difference between the

absorbance of samples and blanks represent the proteolytic activity.
Inhibition values (i) and the percentage inhibitions were calculated as
described in Method I.

Different orders of mixing were also carried out

according to the two procedures used in Method I.
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Pre-incubation studies.

In the pre-incubation studies the inhi

bitor was allowed to react additionally for 15 minutes either with the
enzyme or with the substrate before digestion was started.
were also pre-incubated for the same period of time.

The controls

Digestion was car

ried out according to Methods lA and IB.
Dialysis studies.

In order to know whether the interaction of

inhibitor towards substrate and enzyme is reversible or irreversible,
dialysis studies were carried out at pH 6.4 and pH 7.6.
Regenerated cellulose dialysis tubings^ were cut into pieces of
6-9 inches and thoroughly washed with distilled water.

The tubings were

then immersed in 500 ml of 10 mM sodium edetate solution and heated at
70® - 80® C for 2 hours.

After this, the tubings were allowed to cool,

washed again thoroughly with double distilled water and stored in dis
tilled water at 2® - 4® C in a refrigerator.

Prior to use, the tubings

were soaked in appropriate buffer for 18-24 hours.
The inhibitor was added to the enzyme or substrate and the mix
ture incubated at 37® C for 60 minutes in a metabolic shaker at 200 r.p.m.
A portion of the mixture was then assayed for tryptic activity using
Method I and the rest of the mixture was put in a pre-conditioned dialy
sis tubing sac.

The sac was immersed in 1000 or 2000 ml of 0.1 M phos

phate buffer of appropriate pH and dialysis carried out in a cold room
at 4® C for 96 hours.

The external buffer was continuously stirred with

a stirring magnet and was replaced every 24 hours during the dialysis
period, at the end of which the volume of the contents was measured and
assayed for its tryptic acitivity again.

No significant change in the

^No. 20, 5/8 inches in flat width for trypsin dialysis and
No. 36, 9/8 inches in diameter for casein dialysis.
Average
pore sizes 24®A, Van-Waters and Rogers, Inc., San Francisco,
Calif.
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Figure 2.--Effect of various inhibitor concentrations on the percentage
inhibition of trypsin activity at pH 7.6.
Ten ml of digestion mixture
contained 10 yg enzyme (E) and 50 mg casein (S).
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Figure 3.--Effect of pH and mixing orders on percentage inhibition
of trypsin activity.
Ten ml digest contained, E=20 ug; S=50 mg;
1=10 mg.
Key: 0, inhibitor added to enzyme first; and A, inhi
bitor added to substrate first.
Substrate used was casein.
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TABLE 1

Effect of Various DOSS Concentrations on the Percentage
Inhibition of Trypsin Activity at pH 7.6

Amount of the Components in
10 ml of Digestion Mixture

Absorbance)^ at
280 nm against
Respective
Blanks

Inhibition, % of
Control Activity

Enzyme
(yg)

Substrate^
(mg)

DOSS
(mg)

10

50

Control

0.511

“—

10

50

1

0.423

18.0

10

50

2

0.394

23.0

10

SO

4

0.340

34.0

10

50

8

0.303

41.0

10

50

12

0.266

48.0

10

50

14

0.253

51.0

10

50

16

0.218

58.0

10

50

18

0.187

64.0

10

50

20

0.158

69.0

&Casein
^Average of at least three determinations.
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volume of the sac contents was noticed after dialysis.

A control dialy

sis experiment was run simultaneously in the same way except that the
inhibitor solution was replaced by equivalent amount of buffer solution.
Percentage inhibition values before and after dialysis were calculated
as mentioned in Method I.
All the above experiments were carried out at least in duplicate.

II.

RESULTS AND DISCUSSION

In all the trypsin studies, the inhibitor was added to the enzyme
first (Mixing Order A)

except for the data of Table 2 and Figure 3 in

which case both Mixing

Orders A and B

The inhibitory

effect of DOSS

were used.
on tryptic activity

various inhibitor concentrations using Method I (Table 1).

was studiedat
A biphasic

plot (Fig. 2) resulted on plotting the percentage inhibition against the
inhibitor concentration.

It is possible that at lower concentrations

DOSS inhibits only by interacting with either the substrate or the enzyme
but at higher concentrations of DOSS additional dénaturation of the pro
tein (trypsin or casein) also takes place.

The biphasic plot in Figure 2

can also be explained as due to the saturation of either the enzyme or
the substrate with the inhibitor.

This explanation seems more likely in

the light of the mechanistic studies to be discussed later.
The effect of pH and mixing orders on the percentage inhibition
was also studied using Method I.

The results are shown in Table 2.

plot of these results was made as shown in Figure 3.

A

Figure 3 shows

that when the inhibitor was added to the substrate first (Mixing Order
B), the percentage inhibition remained reasonably constant throughout
the pH range studied.

When the inhibitor was added to the enzyme first
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Figure 4.--Plots of l/vj against 1/S for antitryptic activity
of DOSS at two pH values.
Ten ml digest contained, E=20 pg;
1=10 mg; S=23-50 mg.
K e y : A pH 6.4; and 0, pH 7.6. Substrate
used was casein.
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Figure 5.— Plots of l/v^ against I for antitryptic activity of DOSS at
pH 7.6.
Key: 0, ten ml digest contained E=10 yg, S=50 mg; and A, ten
ml digest contained E=20 yg; S-50 mg.
Substrate used was casein.
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Figure 6 . --Plot of 1/vi against I for antitryptic activity of DOSS at
pH 7.6.
Ten ml digest contained E=30 yg; S=40 mg.
Substrate used was
casein.
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TABLE 2

Effect of pH and Mixing Orders on Percentage
Inhibition of Trypsin Activity by DOSS
in the Presence of a Natural
Substrate, Casein

Amounts of Components in
10 ml of Digestion Mixture

Inhibition^, % of
Control Activity with
pH

Enzyme
(ug)

Substrate
(mg)

DOSS
(mg)

20

SO

10

20

50

20

A

B

6.0

51.67

34.66

10

6.4

53.24

37.54

50

10

6.5

40.15

20

50

10

6.6

37.04

---

20

50

10

6.8

32.55

33.31

20

50

10

7.2

35.64

34.38

20

50

10

7.6

31.97

32.73

20

so

10

8.0

32.25

35.15

^Average of at least four determinations,
^Inhibitor added to enzyme first.
^Inhibitor added to substrate first.
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TABLE 3

Effect of Different Shaking Speeds on the
Percentage Inhibition of Trypsin
Activity by DOSS at pH 7.6

Amounts of Components in
10 ml of Digestion Mixture

DOSS
(mg)

Shaking
Speed
(r.p.m. )

Inhibition^, % of
Control Activity

Enzyme
(ug)

Substrate*
(mg)

20

SO

10

0

32.S6

20

50

10

SO

32. OS

20

SO

10

100

32.37

20

SO

10

200

31.96

^Casein
^Average of at least five determinations.
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TABLE 4

Effect of DOSS on the Reaction Velocities of Casein Digestion
by Trypsin at pH 7.6 at Varying Concentrations of
Substrate and at Fixed Levels of Enzyme and Inhibitor

Amounts of Components in 10 ml
of Digestion Mixture

Absorbance^ at
280 nm against
Respective Blanks

Serial
#
Enzyme, E
(ug)

Substrate, S
(mg)

Inhibitor, I
(mg)

Controls
(V)

With Inhibitor
(Vi)

1

20

23

10

0.522

0.224

2

20

27

10

0.575

0.290

3

20

30

10

0.598

0.320

4

20

33

10

0.620

0.378

5

20

40

10

0.693

0.424

6

20

50

10

0.728

0.512

^Average of two determinations.
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TABLE 5

Effect of DOSS on the Reaction Velocities of Casein Digestion
by Trypsin at pH 6.4 at Varying Concentrations of Substrate
and at Fixed Levels of Enzyme and Inhibitor

Amounts of Components in 10 ml
of Digestion Mixture

Absorbance® at
280 nm against
Respective Blanks

Serial
#
Enzyme, E
(ug)

Substrate, S
(mg)

Inhibitor, I
(mg)

Controls

1

20

23

10

0.368

0.116

2

20

27

10

0.392

0.145

3

20

30

10

0.432

0.168

4

20

33

10

5

20

40

10

0.481

0.175

6

20

SO

10

0.546

0.188

(V )

-

With Inhibitor
Cvi)

0.172

^Average of two determinations.
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TABLE 6

Effect of DOSS on the Reaction Velocities of Casein Digestion by
Trypsin at pH 7.6 at Varying Concentrations of the Inhibitor
and at Different Fixed Levels of Enzyme and Substrate

Amounts of Components in
10 ml of Digestion Mixture

Absorbance^ at 280 nm against
Respective Blanks (v^)

Serial
#
Substrate, S
Crag)

Inhibitor, I
(rag)

A

B

1

SO

-

0.505

0.775

2

SO

2

0.398

0.700

3

SO

4

0.360

0.630

4

SO

8

0.318

0.600

5

SO

12

0.288

O.SOO

6

SO

14

0.280

0.460

7

SO

18

0.219

0.390

8

SO

20

0.180

0.338

^Average of two determinations.
^Amount of enzyme used was 10 yg.
^Amount of enzyme used was 20 yg.
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TABLE 7

Effect of DOSS on the Reaction Velocities of Casein Digestion by
Trypsin at pH 7.6 at Varying Concentrations of the Inhibitor
and at Different Fixed Levels of Enzyme and Substrate

Amounts of Components in
10 ml of Digestion Mixture

Absorbance^ at 280 nm against
Respective Blanks (vi)

Serial
#
Substrate, S
(mg)

Inhibitor, I
(rag)

A

B

0.845

0.913

1

40

2

40

1.25

0,750

0.800

3

40

2.50

0.680

0.732

4

40

5.00

0.635

0.662

S

40

10.00

0.520

0.535

6

40

20.00

0.245

0.290

—

-

^Average of at least two determinations.
^Amount of enzyme used was 30 ug.
^Amount of enzyme used was 40 ug.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

44

(Mixing Order A), the resulting percentage inhibition was found to be
significantly higher (p<0.001 as determined by the student’s t test for
unpaired data) at pH below 6.5.

This marked difference in inhibition

pattern below pH 6.5 will be discussed later.
Data in Table 3 shows the effect of different shaking speeds on
the antitryptic activity of DOSS at pH 7.6.
used as the substrate.

The results

In this study casein was

(Table 3) show that the percentage

inhibition values remain unchanged at various shaking speeds which in
dicates that no mechanical and/or physical forces of shear and viscosity
are involved in the process of inhibition.

Therefore, some stochiomet-

ric chemical interactions between the various components of the reaction
must be operative which results in the inhibitory effect of DOSS.
In order to know the mechanism of inhibition, the effect of DOSS
on the trypsin activity at both pH 7.6 and pH 6.4 were determined using
casein as the substrate (Tables 4-5).

In these studies, the concentra

tions of the inhibitor and the enzyme were kept constant, whereas the
substrate levels were varied.

Effect of DOSS on the reaction velocities

of casein digestion by trypsin at pH 7.6 was also studied varying the
concentration of the inhibitor but keeping the enzyme and the substrate
at different fixed levels (Tables 6-7).

Various graphical methods were

used in order to delineate the particular mechanism of inhibition in
volved.
Using the data from Tables 4 and 5, double reciprocal plots both
at pH 6.4 and 7.6 (Fig. 4) and plots of l/v^ against I at pH 7.6 with
different inhibitor concentrations (Fig. 5-6), indicate substrateinhibitor interaction as the major mechanism of inhibition (27, 109).
Using the data of Tables 4 and 5 plots of S/vj against S (Woolf plots).
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Figure 7.--Plot of (i) against S for antitryptic activity of DOSS at pH
7.6.
Ten ml digest contained E=20 ug; 1=10 mg.
Substrate used was casein.
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Figure 8. — Plot of (i) against S for antitryptic activity of DOSS at pH
6.4.
Ten ml digest contained E=20 yg; 1=10 mg.
Substrate used was casein.
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Vi against vi/S (Hofstee plots) and plots of 1/v against l/I; plots of
i against I from Tables 6 and 7 also yielded curves typical of substrateinhibitor interaction (27, 109).

Plots of fractional inhibition (i)

against S at pH 7.6 (Fig. 7) and at pH 6.4 (Fig. 8) were made.

These

plots suggest that in addition to substrate-inhibitor interaction,
enzyme-inhibitor interaction also contributes to the overall inhibition.
This contribution seems to be least at pH 7.6 (Fig. 7) and most at pH
6.4 (Fig. 8).

This apparent increased involvement of the enzyme with

the inhibitor as a consequence of a change in pH can be well explained
by the fact that DOSS is a molecule carrying a net negative charge and
the trypsin possesses an isoelectric point in the vicinity of pH 7.0
(62).

Therefore, increased amount of inhibition below pH 6.5 is expected.

This explains the increased inhibition below pH 6.5 observed in Figure 3.
Also, the biphasic curve of percentage inhibition against the inhibitor
concentration (Fig. 2), can be explained on the basis of a dual mechan
ism of inhibition involving both the substrate and the enzyme.
Considering the fact that casein has an isoelectric point at
pH 4.2, negatively charged DOSS cannot be expected to interact with the
natural substrate, casein at both pH 6.4 and 7.6.

However a DOSS-

casein interaction is possible in which conformation of the natural pro
tein, casein is changed involving no electrostatic binding,
A general inhibitory mechanism involving a substrate can be due
to (1) substrate depletion,
inhibitor complex,

(2) inhibition of the enzyme by a substrate-

(3) combination of both mechanisms.

Mechanistic

schemes, conservation equations and the various forms of the Michaelis
equation describing these inhibitory systems have been described by
Reiner (91) in detail.

For the case where the effective concentration
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of the substrate decreases as a result of interaction with the inhibitor,
the following scheme may be considered:
ki
E + S

C

E + P

ks
S + I --- => Si
'k-3
Where E, S, I, C, P and

are, respectively, the concentrations of free

enzymes, free substrate, free inhibitor, enzyme-substrate complex, pro
duct and substrate-inhibitor complex and the k ’s are rate constants.
Ej., St and

If

respectively stand for the total amounts of enzyme, sub

strate and the inhibitor, the conservation equations for the above mech
anism can be

written as

follows :

Et =

E+ C

St =

S + S^(Ignoring S bound in C).

It - I+ Si
Considering these conservation equations and making certain mathematical
manipulations, a very useful form of the Michaelis-Menton equation can
be obtained as described by Reiner (91) and given below:

It =

Sjti.
kjn
km_

In this equation It and St have their usual meaning as described earlier
whereas i, Kj and

are, respectively, fractional inhibition, dissocia

tion constant for the substrate-inhibitor complex and the Michaelis
constant.

According to this equation, a plot of It against (i/l-i) must

be hyperbolic in shape with linear asymptotes and different slopes in the
various regions.

When the variable (i/l-i) is small, the second term in

the braces is approximately equal to (St i/l-i).

Thus the initial
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Figure 9 . --Plots of I against (i/l-i) for antitryptic activity
of DOSS at pH 7.6.
K e y : 0, 10 ml digest contained E=20 yg;
S=50 mg; and A, 10 ml digest contained E=10 yg; S=50 mg.
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strate used was casein.
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Substrate used was casein.
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TABLE 8

Effect of Pre-Incubation on Antitryptic Activity
of DOSS at pH 7.6

Inhibition^, % of
Control Activity

Amounts of Components in
10 ml of Digestion Mixture
Substrate/Inhibitor
Enzyme
(yg)

Substrate^
(mg)

30

40

20

30

40

30

I

Inhibitor
(mg)

A

B

C

2

71.0

6 6 .5

88.6

10

4

38.5

39.2

6 6 .4

40

5

8

25.0

25.0

45.5

30

40

2.5

16

19.5

21.8

36.7

30

40

1.25

32

11.2

10.0

23.4

^Casein.
t*An average of two determinations.
^No pre-incubation.
®The inhibitor pre-incubated with casein for IS minutes.
Cphe inhibitor pre-incubated with trypsin for 15 minutes.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

52

TABLE 9

Irreversible Binding of DOSS to Enzyme (Trypsin)
and Substrate (Casein)

[
I

pH

Component
Bound to
the Inhibitor
before
Dialysis

Amount of the Components in
10 ml of Digestion Mixture

Percentage
Inhibition^ of
Control Activity

Enzyme
(Pg)

Inhibitor
(mg)

Before
Dialysis

After
Dialysis

Substrate
(mg)

Trypsin

10

50

1.0

100.0

100.0

Trypsin

10

50

0.1

65.0

57.5

Trypsin

20

50

0.1

94.4

95.0

Casein

20

50

10.0

42.0

38.0

Tryspin

10

50

1.0

65.6

67.6

Casein

20

50

10.0

36.7

34.3

6.4

7.6

^Average of at least two determinations.
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TABLE 10

Effect of Incubation Time on Percentage Inhibition
of Trypsin Activity by DOSS at pH 7.6

Amounts of Components in
10 ml of Digestion Mixture

Inhibitor
(mg)

Incubation
Time
(Mrs)

Inhibition^, % of
Control Activity

Enzyme
(Eg)

Substrate^
(mg)

10

50

10

0.333

57.5

10

50

10

0.666

57.3

10

50

10

1.000

55.0

10

50

10

1.333

47.6

10

50

10

1.666

41.0

10

50

10

2.000

40.4

10

50

10

2.500

39.1

^Casein.
^Average of two determinations.
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portion of the curve is linear, with slope
As (i/l-i) becomes infinite

= CK3 + 8% ) Cl + S^/K^).

(as will be the case when i approaches 1),

the entire second term in the braces approaches a constant.
term is still linear.

Hence the asymptone should be again linear, with

slopey 2 = K3 (1 + S-^/Kj^), which is
The

The first

shapes of such plots

smaller than the initial

slope.

(Fig. 9) for dioctyl sodium sulfosuc-

cinate at pH 7.6, using casein as the substrate and resulting from Table
6 , are typical of substrate depletion.

Similar plots showing substrate

depletion as the basic mechanism were also obtained using different sub
strate and enzyme concentrations (Table 7).
Pre-incubation studies (Table 8) show that pre-incubation of the
substrate with the inhibitor bears no significant effect on the inhibi
tion.

Pre-incubation of the enzyme with the inhibitor prior to digestion

seems to increase the percentage inhibition at almost all substrate/
inhibitor ratios.

These results suggest that, besides substrate-inhibitor

interaction, enzyme-inhibitor interaction is also a part of the overall
mechanism of inhibition at pH 7.6.
has already
The

This is in good agreement with what

been concluded from the mechanistic studies.
results of the dialysis

studies (Table 9) show that percent

age inhibition values after dialysis are similar to the ones before
dialysis, indicating no net gain in enzyme activity due to dialysis.
Therefore, it seems that DOSS binds both casein and trypsin irreversibly
both at pH 6.4 and pH 7.6.
Effect of incubation time on the antitryptic activity of DOSS
was studied using Method I at pH 7.6 (Table 10).

A plot of percentage

inhibition against the incubation time was made (Fig. 10).

Figure 10

indicates an initial slow fall in the percentage inhibition, followed by
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TABLE 11

Effect of pH and Mixing Orders on the Antitryptic
Activity of DOSS in the Presence of a
Synthetic Substrate, DL-BAPNA

Amounts of Comnonents in
8 ml of Reaction Mixture

Percentage inhibition®
of Control Activity with
pH

Enzyme
(Pg)

Substrate
(mg)

20

2.175

250

20

2.175

250

Inhibitor
(Pg)

A

B

6.4

29.20

9.43

8 .2

27.00

12.70

^Average of at least three determinations.
^Inhibitor added to enzyme first.
^Inhibitor added to substrate first.
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a rapid decrease and a successive slow fall in the percentage inhibition.
Such a continuous decrease in the percentage inhibition with time can be
explained by considering the following simultaneous reaction taking place
in the system;
E + S ÿ

> P + E

(A)

S + I ---- > SI

(B)

It seems possible that in the beginning, reaction

(B) proceeds at a com

paratively faster rate (Probably due to higher affinity of the inhibitor
for S as compared to that of E for S ) , followed by saturation of I with
S to give the SI complex which is then followed by a relatively slower
rate of reaction (A) in the forward direction [due to depletion of S and
accumulation of products in (A)].

Such an explanation of Figure 10 is

consistent with the mechanistic evidence and the pre-incubation studies
discussed previously.

The shape of curve in Figure 10 can also be ex

plained by considering the following mechanism of inhibition:
E + I

El

S + I

» SI

E + S --- ^ P + E
According to this mechanism a reversible enzyme-inhibitor complex is
formed, followed by substrate-inhibitor interaction which then saturates
and thus

results

into a successive decrease in percentage inhibition

with time in Figure 10.

The occurence of such a mechanism in the present

studies is very unlikely since the results of dialysis studies indicate
that the formation of

Elcomplex

The effect of mixing orders

is irreversible.
on the antitryptic activity of DOSS

was studied both at pH 6.4 and pH 8.2 using DL-BAPNA as the synthetic
substrate

(Table 11).

The results suggest the involvement of an enzyme-
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Figure 11.--Plot of l/v^ against 1/S for antitryptic activity of DOSS
at pH 8.2.
Eight ml of incubation mixture contained H=40 yg; 1=0.25 mg;
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Figure 12.--Plot of 1/v against 1/S for inhibition of trypsin activity
by DOSS at pH 6.4.
Eight ml of incubation mixture contained E=40 yg;
S=lxlO-G - 5x10-6 moles.
Key: Û, no inhibitor added; and 0, 1=0.25 mg.
Substrate used was DL-BAPNA.
Both lines were drawn by the method of
least squares.
A, y=19.97 x + 1.14 (r=0.990); 0, y=35.94 x + 0.95
(r=0.990).
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TABLE 12

Effect of DOSS on the Reaction Velocities of DL-BAPNA Hydrolysis
by Trypsin at pH 8.2 at Varying Concentrations of the
Substrate and at Fixed Levels of Enzyme and Inhibitor

Difference in Absorbance^
of Samples and Their
Respective Blanks at
410 nm Against
Distilled Water

Amounts of Components in
8 ml of Reaction Mixture
Serial
#
Enzyme, E
(yg)

Substrate, S
Cum)

Inhibitor, I
(ug)

Controls

1

40

1.0

250

0.098

0.046

2

40

1.3

250

0.120

0.058

3

40

1.5

250

--

0.065

4

40

2.0

250

0.174

0.071

5

40

3.0

250

0.191

0.084

6

40

4.5

250

-

0.090

7

40

5.0

250

0.263

---

With Inhibitor

(V )

^Average of two determininations.
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TABLE 13

Effect of DOSS on the Reaction Velocities of DL-BAPNA Hydrolysis
by Trypsin at pH 6.4 at Varying Concentrations of the
Substrate and at Fixed Levels of Enzyme and Inhibitor

Difference in Absorbance^
of Samples and Their
Respective Blanks at
410 nm Against
Distilled Water

Amounts of Components in
8 ml of Reaction Mixture
Serial
#
Enzyme, E
(yg)

Substrate, S
(ym)

Inhibitor,
(yg)

I

Controls
(V)

With Inhibitor
(vi)

1

40

1.0

250

0.048

0.026

2

40

1.3

250

0.060

0.037

3

40

1.5

250

0.068

0.042

4

40

2.0

250

0.089

0.051

5

40

3.0

250

0.126

0.077

6

40

4.5

250

0.169

0.108

^Average of two determinations.
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inhibitor interaction at both pH values.

However, no conclusion can be

drawn as far as the involvement of a substrate-inhibitor interaction is
concerned.

Therefore, data for double reciprocal plots (Tables 12-13)

were obtained using a synthetic substrate (Method II).
procal plot

A double reci

(Fig. 11) at pH 8.2 indicates that the substrate-inhibitor

interaction is the overall mechanism of inhibition, however, direct
enzyme inhibition may also be involved.

Such a mechanism was further

confirmed to exist by making Hofstee and Woolf plots using the data of
Table 12.

This mechanism of inhibition seems to be similar to the one

observed when casein was used as the substrate (Fig. 4).

This similar

ity in mechanisms, when two different substrates were used, may indicate
that the interaction between the inhibitor and casein molecules involves
some primary sites of the natural proteins.

However, a double reciprocal

plot at pH 6.4 with DL-BAPNA as substrate (Fig. 12) was found to be
typical of a true competitive inhibition involving the enzyme-inhibitor
interaction but no substrate-inhibitor interaction.

Such a mechanism

was further confirmed by making corresponding Woolf and Hofstee plots.
Lack of substrate-inhibitor interaction in the presence of synthetic
substrate at pH 6.4 may be attributed to the higher affinity of trypsin
for DOSS which is expected at pH 6.4, considering the facts that trypsin
has an isoelectric point of 7.0 and that DOSS assumes a net negative
charge.
In summary, inhibition of tryptic activity by DOSS in the pres
ence of a natural substrate, involves substrate-inhibitor interaction
involving substrate depletion as the major mechanism at both pH 6.4 and
pH 7,6, however some direct enzyme inhibition may also occur.

Direct

inhibitory effect of DOSS against trypsin seems to be enhanced at pH
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values below 6.5.

In the presence of a synthetic substrate, at pH 8.2

the inhibitory mechanism seems to be similar to the one outlined for
the natural substrate, but at pH 6.4 a true competitive enzyme inhibi
tion forms the only mechanism.
Pancreatitis is a chemical autolytic process with a well docu
mented pathogenesis

(15).

Although various mechanisms underlying the

pathological process have been reported (1, 25, 30, 38, 94) no single
exact mechanism has been established.

Nevertheless, evidence is avail

able that trypsin plays a central role in the pathogenesis of the disease
irrespective of the mechanism involved (22, 23, 43, 74, 80-82).

It is

then apparent that means of controlling the undesirable hypertryptic
activity at the site of disease could serve as an approach to alleviate
and control the disease.
such as

soybean

In fact the use of various trypsin inhibitors

inhibitor, ovomucoid inhibitor and trasylol, a bovine

inhibitor (74, 108) has been reported in the treatment of pancreatitis.
Although trasylol has found significant place as an antipancreatitis
agent in human medicine, other inhibitors have proven effective and use
ful only in vitro and/or in animals.

Therefore in view of the various

possible mechanisms of the disease process and even more complicated
situation in vivo, one must exercise great care in projecting the in
vitro data to the clinical situation.

In summary, an effective and

useful antipancreatitis agent in vivo must exhibit the following charac
teristics:

(1) The inhibitor must not be species specific and should

possess a reasonably broad inhibition spectrum.

(2) Molecule should have

a low molecular weight to permit faster diffusion into the focus of in
flammation and should possess a membrane permeability equivalent to that
of the enzyme molecule.

(3) It should irreversibly bind the enzyme and
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should show significant inhibition in the presence of both natural and
synthetic substrates.

(4) The inhibition constant (K^) must be smaller

than the affinity constant between the enzyme and the substrate.

This

is absolutely necessary because concentration of the enzyme to be inhi
bited in vivo are roughly lOr? - 10"^ moles/liter.

(5) The inhibitor

must have high compatibility, nontoxicity, nonallergic and noninflam
matory properties.

(6 ) It should not interfere with the trypsin inhi

biting power of plasma.

(7) It should have few accessory sites of

binding, and low rates of degradation and excretion thus ensuring higher
bioavailabilities at the site of disease.

(8) It should be appreciably

absorbed into systemic circulation.
Although trasylol is an effective antipancreatitis agent, it has
a very high molecular weight and inhibits reversibly with a very low
rate of inhibition.

Soybean inhibitor shows lower inhibitory effect

with natural substrates than with synthetic ones (108).

It does not

inhibit the release of kinins by trypsin in vivo.
DOSS is a molecule with relatively lower molecular weight and is
currently used in medicine as a fecal softener to relieve constipation
associated with hard, dry stool.

Until recently this compound has been

generally promoted as nonabsorbable, nontoxic and a systemically inert
pharmacological agent.

However recent investigations of Dujovne and

Shoeman (28) have shown that DOSS is considerably absorbed into the
systemic circulation in rats and humans after its oral administration.
Along with this finding, the present inhibitory studies with DOSS, sug
gest a possible use of this medicinal surfactant in pancreatitis.

The

results of the present studies indicate that besides its direct inhibi
tory effect against trypsin, the interaction of DOSS with casein may
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suggest the possibility of a similar interaction between the inhibitor
molecule and the glycoproteins at the site of inflammation.

Such an

interaction in vivo may prove to be useful in protecting the site from
necrosis and erosion

(5).

Moreover irreversible binding of DOSS with

trypsin and casein, its smaller molecular weight as compared to protein
inhibitors, and its excretion in bile (28) may prove to be useful charac
teristics of DOSS as an antipancreatitis agent.
The inhibitory studies with DOSS also suggest that possible drug
interactions may arise in the course of therapy with DOSS in situations
and conditions where concomitant use of proteolytic enzymes like trypsin
and chymotrypsin is desirable for the simultaneous treatment of disorders
like indigestion, inflammation, injury, b u m s , pulmonary alveolar pro
teinosis, surgery, episiotomies and blood clotting.

Drug interactions

are also possible with drug esters like penamecillin and chloramphenicol
palmitate and certain N-acylated drugs when given orally along with DOSS.
Such drugs are usually acted by proteinases in the gastrointestinal
tract resulting in changed chemical and/or pharmacological activity.
These drug interactions may be difficult to recognize, particularly when
DOSS is used as an excipient, either for the formulation of these drugs
mentioned above or any other drug being used simultaneously.
Present studies also suggest that the use of DOSS as one of the
adjuvants in insulin dosages may improve its oral absorption as certain
proteinase inhibitors such as trasylol have been shown to increase in
sulin absorption when administered together (44, 65).

Such an enhance

ment of absorption can be further augmented by the recent studies of
Gouda (41, 59, 71) in which DOSS has been shown to enhance the absorption
of drugs through membranes of various complexities.
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CHAPTER V

STUDIES WITH PEPSIN

I.

EXPERIMENTAL

Materials
The following chemicals were used in these studies:
Pepsin (from hog stomach mucosa, 3 x crystallized, lyophilized).
Nutritional Biochemicals Corporation.
Hemoglobin

(denatured, standardized for protease assay).

Nutritional Biochemicals Corporation.
N-Acetyl-L-phenylalanyl -L-diiodotyrosine

(APD).

Sigma Chemical Company.
Dioctyl sodium sulfosuccinate

(DOSS).

"Aerosol 0. T. 100%", Sargent-Welch Scientific Company.
Ninhydrin.
J. T. Baker Chemical Company.
Isopropyl alcohol (2-propanol).
J. T, Baker Chemical Company.
Methyl Cellosolve (ethylene glycol monomethyl ether).
Fisher Scientific Company.
All other chemicals used were either U.S.P. or reagent grade.

Procedures
Methods for Antipeptic Activity.

Two different methods for de

termining the antipeptic activity were used.
65
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Method I.

In this method, denatured hemoglobin is digested under

standard conditions.

The undigested hemoglobin is precipitated with tri

chloroacetic acid, and the amount of unprecipitated protein is estimated
spectrophotometerically in u. v. range.

The method used was essentially

that of Rajgopalan, Moore and Stein (90).
in the procedure were made.

However a few modifications

The substrate, enzyme and inhibitor solu

tions of various concentrations were prepared either in HCl
distilled water.

(pH 1.8) or

All solutions were finally adjusted to pH 1.8, were

freshly prepared and were brought to 37® C before mixing.
One milliliter of the enzyme solution was pipetted into each of
the flasks already maintained at 37° in a metabolite water bath shaker.
Subsequent to this 1 ml of the inhibitor solution was added to each flask
followed by 2 ml of the substrate solution.
bated for 5 minutes at 37® C with no shaking.

All the samples were incu
At the end of the incuba

tion period, 4 ml of 5% trichloroacetic acid was added to each sample in
the same order and thoroughly mixed.
mixture was kept at 8 ml in all cases.

The final volume of the incubation
The incubation mixtures were

allowed to remain at 37® C for 3 minutes and were then filtered through
Whatman #2 filter paper.

Blank determinations were carried out exactly

in the same way as samples except that the substrate solution was added
after the addition of trichloroacetic acid.

The absorbance of all the

filtrates was read at 277 nm against distilled water using a Beckman
ACTA c m

Spectrophotometer.

inhibition experiment.

Controls were simultaneously run for every

The controls differed from the samples in having

inhibitor solution replaced by equivalent amounts of HCl (pH 1.8).
Differences between the absorbance of samples and their respec
tive blanks represent the peptic activities and were used as measures of
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reaction velocities in all kinetic studies.

Inhibition values

(i) and

the percentage inhibitions were calculated as described previously under
Method I for antitryptic activity.
Method II.

In this method, N-Acetyl-L-phenylalanyl-L-diiodo-

tyrosine (APD) is used as the substrate.

APD is a low molecular weight

synthetic peptide that is easily hydrolysed by pepsin.

The extent of

hydrolysis is determined by measuring the ninhydrin color given by the
newly formed L-diiodotyrosine.

The assay procedure used was that of

Jackson et al (57) with slight modifications.

Various reagents used in

this method were prepared as follows:
Enzyme and inhibitor solutions.

Various concentrations of the

enzyme and the inhibitor solutions were prepared as in Method I except
that all the solutions were finally adjusted to pH 2.00.
Substrate solutions.
dissolve directly at pH 2.00.

The substrate was extremely difficult to
Therefore, a stock solution (20x10“^M) of

the substrate was prepared by first dissolving 12.444 mg of APD in about
40 ml of 0.01 N NaOH solution and then adjusting the pH of the solution
to 2.00 with HCl.

Final volume of the substrate solution was made to

100 ml with HCl at pH 2.00.

Various concentrations used could be ob

tained by further diluting the stock solution with HCl.

These solutions

were used within 30-60 minutes after preparation since material precipi
tates on prolonged standing.
Acetate buffer (pH 5.5-5.4).

Sixty-seven milliliter of glacial

acetic acid and 360 g of sodium acetate (CH3C00Na-3H 2O) were dissolved
in 270 ml of distilled water and made up to 1000 ml with H2O.
Cyanide-acetate buffer solution.

Forty-nine milligram of this

solution was taken into a volumetric flask and made up to 1000 ml with
more acetate buffer.
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Ninhydrin solution.

Three grams of ninhydrin was dissolved in

100 ml of methyl cellosolve (ethylene glycol monomethyl ether).
All the substrate, enzyme and inhibitor solutions were freshly
prepared and were brought to 37* C before mixing.

The final volume of

the reaction mixture was kept at 9 ml in each case.
A series of test tubes were set up and preequilibrated at 37* C
in a metabolic water bath.

One milliliter of the enzyme solution was

added to each tube followed by the addition of 1 ml of the inhibitor
solution.

Three milliliter of the substrate solution was then added to

each of the tubes and the samples incubated at 37* C for 10 minutes with
no shaking.

The reaction was stopped by adding 0.5 ml of N/2 NaOH into

each of the test tubes.

All the tubes were well shaken.

Five-tenths

milliliter of cyanide-acetate buffer solution was then added to each
tube followed by 0.5 ml additions of ninhydrin solutions.

Without any

shaking all the tubes were placed in a boiling water bath for 15 minutes,
after which 2.5 ml of isopropylalcohol was added to each tube and allowed
to cool at room temperature.

The extent of hydrolysis was determined by

measuring the ninhydrin color given by the newly formed L-diiodotyrosine.
This was done by recording the absorbance of the reaction mixtures of
both samples and blanks at 570 nm against distilled water using a Beck
man ACTA c m

Spectrophotometer.

All blanks and controls were prepared simultaneously as described
for Method I.

The peptic activities, reaction velocities and the inhibi

tion values were determined as indicated in Method I.
Various orders of mixing.

Two different orders of mixing were

used, namely Mixing Order A and Mixing Order B.
described in Chapter IV.

These have already been

In all the pepsin studies involving Method I,
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Figure 13.— Effect of pH and mixing orders on percentage inhibition of
pepsin.
Eight ml of digest contained E=10 ug; S=2 mg; 1=200 ug.
Key:
0, inhibitor added to enzyme first; and A, inhibitor added to substrate
first.
Substrate used was hemoglobin.
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Figure 14.--Plot of 1/vi against 1/S for antipeptic activity of DOSS at
pH 1.8.
Eight ml digest contained E=10 pg; 1=200 ug; S=0.8-2.0 mg.
Substrate used was hemoglobin.
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Figure 15.--Plot of 1/vi against I for antipeptic activity of
DOSS at pH 1.8.
Eight ml digest contained E=10 ug; 8=2 mg.
Substrate used was hemoglobin.
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TABLE

14

Effect of Various Concentrations of DOSS on the
Percentage Inhibition of Pepsin
Activity at pH 1.8

Amounts of the Components
in 8 ml of Digest

Enzyme
CPg)

Substrate^
(mg)

Inhibitor
(Pg)

Percentage
Inhibition^
of Control
Activity

4

1.2

50

4

1.2

100

4

1.2

200

72.0

4

1.2

300

100.0

4

1.2

500

100.0

4

1.2

1000

100.0

-

-

^Hemoglobin
^Average of at least three determinations.
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TABLE 15

Effect of pH and Mixing Orders on Percentage Inhibition of
Pepsin Activity by DOSS in the Presence of a
Natural Substrate, Hemoglobin

Amounts of Components in
8 ml of Digest

Percentage Inhibition
Control Activity
pH

Enzyme
(Pg)

Substrate
(mg)

Inhibitor
(yg)

A

B

10

2.0

200

1.5

64.40

58.10

10

2.0

200

1.8

57.20

41.00

10

2.0

200

2.1

64.90

42.50

10

2.0

200

2.4

58.20

45.20

10

2.0

200

2.7

65. 20

44.90

10

2.0

200

5.0

63.40

44.10

^Average of four determinations.
^Inhibitor added to enzyme first.
^Inhibitor added to substrate first.
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TABLE 16

Effect of DOSS on the Reaction Velocities of Hemoglobin
Digestion by Pepsin at pH 1.8 at Varying Concentrations
of Substrate and at Fixed Levels
of Enzyme and Inhibitor

Amounts of Components in
8 ml of the Digest
Serial
#

Difference in Absorbance®
of Samples and Their
Respective Blanks at
277 nm Against
Distilled Water

Controls
(v)

With Inhibitor
(Vi)

0.2

0.080

0.022

1.2

0.2

0.102

0.034

10

1.4

0.2

0. 124

0.054

10

2.0

0.2

0.184

0.085

Enzyme, E
(ug)

Substrate, S
(mg)

1

10

1.0

2

10

3

4

Inhibitor, I
(mg)

^Average of two determinations.
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TABLE 17

Effect of DOSS on the Reaction Velocities of Hemoglobin
Digestion by Pepsin at pH 1.8 at Various Concentrations
of the Inhibitor and at Fixed Levels
of Enzyme and Substrate

Amounts of Components in
8 ml of the Digest

Inhibitor, I
(mg)

Difference in Absorbance^
of Samples and Their
Respective Blanks at
277 nm Against
Distilled Water

Serial
#
Enzyme, E
(ug)

Substrate, S
(mg)

1

10

2.0

"-

0.193

2

10

2.0

0.08

0.139

3

10

2.0

0.16

0.106

4

10

2.0

0.24

0.087

5

10

2.0

0.32

0.068

6

10

2.0

0.40

0.050

^Average of two determinations.
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Mixing Order A was used except for the data of Figure 13 and Table 15 in
which case both mixing orders were used.

Only Mixing Order A was used

in all the studies using Method II.

II.

RESULTS AND DISCUSSION

The inhibitory effect of DOSS on pepsin activity was Studied at
various inhibitor concentrations using Method I.

The data is presented

in Table 14, which shows a significant inhibitory effect at all concen
trations above 12.5 yg/ml in the system.

The effect of pH and mixing

orders on the percentage inhibition was also studied using Method I
(Table 15).

The data was plotted as shown in Figure 13.

Figure 13 shows

a higher percentage inhibition with Mixing Order A (inhibitor added to
the enzyme first) as compared to Mixing Order B (inhibitor added to the
substrate first).

This increase in inhibition as a consequence of mixing

order seems to be almost constant over the pH range 1.8-3,0.

However at

pH 1.5, no significant increase in the percentage inhibition is indicated.
The marked difference in the inhibition pattern over the pH range 1.82.0 may suggest an enzyme-inhibitor interaction taking place.
be discussed later.

This will

However lack of increased inhibitory effect of DOSS

at pH 1.5 may be accounted for by the fact that pepsin possesses a pH
optimum range of 1.6-3.2 for its maximum activity.
The effect of DOSS on the reaction velocities of hemoglobin
digestion by pepsin at pH 1.8 was studied using various concentrations
of substrate

(Table 16) and inhibitor (Table 17).

Using these data, a

plot of 1/vi against 1/S (Fig. 14) and a plot of l/v^ against I (Fig. 15)
were made.

Both of these plots indicate substrate-inhibitor interaction

as the major mechanism of inhibition (27, 109).

Using the data of
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Figure 16.--Plot of I against (i/l-i) for antipeptic activity of DOSS
at pH 1.8.
Eight ml digest contained E=10 ug; 8=2 mg. Substrate used
was hemoglobin.
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40

30

20

10

1/S
Figure 17.--Plot of 1/v against 1/S for antipeptic activity
of DOSS at pH 2.0.
Nine ml of incubation mixture contained
E=60 ug; 8=10x10-8 _ 50x 10*8 moles.
Key: 0, no inhibitor
added; and A, 1=50 ug.
Substrate used was APD. Both lines
were drawn by the method of least squares.
A, y=22.9400 x +
6.5500 (r=0.9900); 0, y=13.3580 x + 6.2712 (r=0.09972).
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Figure 18.— Plot of 1/vi agasint I for antipeptic activity of DOSS
at pH 2.0.
Nine ml of incubation mixture contained E=60 yg.
Key: A, 5=2.2x10“^ moles; 0, S=4.4xl0"^ moles.
Substrate used
was APD.
Both lines were drawn by the method of least squares.
A, y=1.4729 x + 14.694 (r=0.9948); 0, y=0.3166 x + 11.1520 (r=0.9415)
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TABLE 18

Effect of DOSS on the Reaction Velocities of APD Hydrolysis
by Pepsin at pH 2.0 Using Various Concentrations of the
Substrate and at Fixed Levels of Enzyme and Inhibitor

Amounts of Components in
9 ml of Reaction Mixture

Difference in Absorbance^
of Samples and Their
Respective Blanks at
570 nm Against
Distilled Water

Serial
#
Enzyme, E
(Pg)

Substrate, S
(20xl0-8)m

Inhibitor, I
(Pg)

Control
(v3

With Inhibitor
(Vi)

—-

1

60

0.5

50

0.030

2

60

0.7

50

---

0.026

3

60

1.0

50

0.054

0.033

4

60

1.5

50

0.064

5

60

2.0

50

0.077

0.058

60

2.5

50

0.084

0.067

^Average of two determinations.
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TABLE 19

Effect of DOSS on the Reaction Velocities of APD Hydrolysis by
Pepsin at pH 2.00 at Various Concentrations of the Inhibitor
and at Different Fixed Levels of the Substrate and Enzyme

Amounts of Components in
9 ml of Reaction Mixture
Serial
#
Enzyme, E
(vg)

Difference in Absorbance^
of Samples and Their
Respective Blanks at
570 nm Against
Distilled Water

Inhibitor, I
(ug)

A

B

1

60

:--------

0.061

0.097

2

60

25

0.044

0.077

3

60

50

0.032

0.059

4

60

75

0.024

0.057

S

60

100

0.019

0.056

^Average of two determinations.
^Amount of substrate used was (20x10"®) moles.
®Amount of substrate used was

(40x10“®) moles.
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Figure 14 and Figure 15, plots of S/vi against S,

against v^/S; and

1/i against l/I also yielded curves typical of substrate-inhibitor inter
action (27, 109).

Further characterization of this mechanism was done

by making a plot of I against i/(l-i)

(Fig. 16), which shows substrate

depletion to be the basic mechanism involved (91).
Using the data of Figure 14, a plot of i against S was also made.
This plot indicated that in addition to substrate-inhibitor interaction,
enzyme inhibitor interaction may also be involved in the overall mechan
ism of inhibition.

This seems to explain the increased percentage inhi

bition with Mixing Order A found over the pH range 1.8-3.0 in Figure 13.
Such an additional enzyme-inhibitor interaction could have been further
confirmed to exist through preincubation studies but such studies were
not feasible due to the autodigestion of pepsin under the conditions as
reported earlier (86) and also found in the present investigation.
Effect of DOSS on the reaction velocities of APD hydrolysis by
pepsin at pH 2.00 (Method II) was studied using various concentrations
of the substrate (Table 18) and inhibitor (Table 19).
cal plot

(Fig. 17) was made using the data of Table 18.

A double recipro
Figure 17 is

typical of a true competitive inhibition due to a competition between the
substrate and the inhibitor molecules for the similar site at the enzyme
surface (87).

Such a mechanism was further confirmed by making a plot

of 1/v against I (Fig.

18).

The value of the inhibitor constant (k^)

was also determined from this plot (27),
From the foregoing discussion, it is apparent that DOSS interacts
with both the substrate and the enzyme, when the substrate used is a
natural protein, hemoglobin.

On the other hand, it binds the enzyme

molecule exclusively and shows no affinity for the substrate when the
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substrate used is a synthetic dipeptide, N-Acetyl-L-phenylelanyl-Ldiiodotyrosine

(APD).

Lack of interaction between APD and DOSS and sig

nificant interacting capacity of DOSS for hemoglobin are some of the
typical inhibitory characteristics of the sulfated macroanion inhibitors
of pepsin reported earlier (88).

These similarities in the inhibitory

characteristics between DOSS and macroanion inhibitors may be a conse
quence of their structural similarities.

However, the interaction be

tween DOSS and pepsin in the presence of both a natural and a synthetic
substrate seems to be an additional inhibitory feature of DOSS and is
not exhibited by macroanion inhibitors (88).

Such an enzyme inhibiting

property may be attributed to higher water solubility, surface active
properties, or a relatively lower molecular weight of DOSS.

It is also

possible that DOSS may have a molecular size and shape that highly favors
the hydrophobic and steric considerations important in the orientation
and proximity effects necessary for its binding to the catalytic site at
the surface of the enzyme.

The mechanistic studies also reveal that DOSS

seems to possess a lower affinity for pepsin than for hemoglobin in the
presence of the two.

Such a behavior has also been reported to be shown

by some macroanion inhibitors of pepsin (5).

Lack of interaction between

DOSS and APD but significant interaction between DOSS and hemoglobin, may
also indicate the fact that DOSS probably alters the conformation of the
natural protein, hemoglobin and no involvement of the primary structure
takes place.
Medical treatment of peptic ulcers has been as controversial as
the nature of the disease itself.

The nature of treatments proposed

have ranged from gastric freezing to a wide variety of possible diets to
psychotherapy (50).

Today, the most reliable clinical regimens of
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treatment depend on an elaborate group of intertwined therapeutic ap
proaches

(50).

These may include rest, diet, antacids, anticholinergics,

sedatives, tranquilizers, and psychotherapy.

Although these approaches,

when chosen and applied rationally to the individual patient, have proven
useful in relieving symptoms and in fascilitating healing, none of these
modes of treatment have proven effective in initiating and accelerating
the healing of ulcers.

In this regard pepsin inhibitors both direct and

indirect have gained much significance in experimental and clinical
ulcers

(2-4, 13, 26, 31, 36, 49, S3, 72, 88, 105, 107).

However these

antiulcer agents are not capable of providing the quick symptomatic
relief characteristic of antacids.
three aims:

Thus, an effective ulcer therapy has

alleviation of the complaints, acceleration of the healing

and prevention of recurrency.

The important therapeutic properties of a

successful antiulcer agent may be outlined as follows:

(1) It should

immediately neutralize the gastric hyperacidity and preferably should
elevate the gastric pH to the range between 4 and 5.

This will help in

removal of pain and elevating the pH would ensure inactivation of exist
ing pepsinogen and pepsin in the gastric juice.
effect on peptic activity of gastric juice.

(2)

A direct inhibitory

Such an action may be

achieved through complexation, inactivation or adsorption of the active
enzyme on the inhibitor molecule.

(3)

An indirect inhibitory effect of

peptic activity which may be achieved by interaction of the inhibitor
with one or more components which act as the natural substrates for
pepsin.

(4) The therapeutic agent must be capable of initiating the

onset of healing.

Such an effect is possible if the inhibitor can ir

reversibly complex with the cell components of the mucosal tissue and
thereby form an insoluble crater at the ulcerated site.

Such a
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complexation will also be helpful in protecting from further necrosis
and erosion.

(5) It should decrease the gastric secretion of acid and

pepsin that is due to vagal stimulation.

(6) The therapeutic agent must

have long gastric half life and should decrease the motility.

(7) It

should have reasonably greater buffering capacity and should also inhibit
the release of kinins and any chemotactic factor involved in the process
of inflammation.
Compounds like hexasosamines, hyaluronic acid, mucopolysaccha
rides and certain glycoproteins seem to be present at higher concentra
tion and in more reactive forms at the ulcerated tissue than at the
normal surrounding cells

(110).

Many macroanion sulfated polysaccha

rides and even some other compounds such as ulcerine, carbanoxolone
sodium and bicitropeptide (a bismuth proteinate) have been shown to
possess their antipeptic activity and hence their antiulcerogenic action
due to their ability to form insoluble complexes with these tissue de
gradation products

(99, 110, 111).

An ulcerated site covered with such

a complex has been believed to be shielded from further exposure to the
damaging effects of the acidic gastric juice and pepsin and thus result
ing into healing of the ulcer.
In view of the mechanistic evidence, DOSS may provide a possible
antiulcer action through such an indirect mechanism.

It may also exert

additional healing effect due to its direct inhibitory effect against
pepsin.

Pepstatin, a pentapeptide marketed by Banayu Pharmaceutical Co.

is perhaps the most effective pepsin inhibitor in ulcers which acts
through such a direct inhibitory action against pepsin (72).

Further

more, the findings by Lish (69) that DOSS exerts a potent inhibitory
effect on the volume of secretions and on the amount of acid secreted
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when administered intraduodenally to rats, may further enhance the anti
ulcerogenic effect of this compound.
A reduction in the digestive capacity of the gastric juice for
food proteins may be a consequence of the use of DOSS as an antiulcer
agent.

Drug interactions with certain prodrugs and proteolytic enzymes

are possible.

These interactions have already been discussed in Chapter

IV.
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CHAPTER VI

SUMMARY

Dioctyl sodium sulfosuccinate is an anionic surfactant widely
used in medicine as a fecal softener.

Inhibitory effect of this medi

cinal surfactant on the proteinase activity of trypsin and pepsin was
studied in vitro using both natural and synthetic substrates.

The in

fluence of various reaction conditions such as pH, mixing order, ratio
of the components, preincubation, incubation time, and shaking rates on
the inhibitory effect of the medicinal surfactant were studied.

Kinetic

studies were carried out using initial velocities and the mechanisms of
inhibition were delineated employing various graphical techniques.
Mechanistic studies indicate that the inhibition of tryptic ac
tivity by dioctyl sodium sulfosuccinate in the presence of a natural
substrate, involves substrate-inhibitor interaction involving substrate
depletion as the major mechanism at both pH 6.4 and pH 7.6.
direct enzyme inhibition may also occur.

However some

In the presence of a synthetic

substrate, at pH 8.2, the inhibitory mechanism seems to be similar to the
one outlined for the natural substrate, but at pH 6.4 a true competitive
enzyme inhibition forms the only mechanism.

The interactions of the in

hibition with the enzyme and the substrate were found to be irreversible
through dialysis studies.
Mechanism of inhibition for pepsin was found to be similar to
that of trypsin with the natural substrate.

With the synthetic substrate,

87
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the inhibition of pepsin at pH 2.00 was also found to be due to a compe
tition between the substrate and the inhibitor molecules for the enzyme.
Possible therapeutic significance of the inhibitory effect of
this medicinal surfactant was discussed suggesting possible use of dioctyl
sodium sulfosuccinate in the treatment of peptic ulcers and pancreatitis.
Biopharmaceutical implications of the study were also discussed.
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APPENDIX

BASIC KINETIC MECHANISMS OF ENZYMES

Enzymes may be defined as the biocatalysts in the living organ
ism.

The most characteristic property and function of enzymes is the

catalysis of chemical reaction.

These reactions are complicated pro

cesses which are made up of a series of steps involving a number of
intermediates.

Following are some of the important experimental ap

proaches which have contributed to the present knowledge of the various
characteristic behaviors of enzymes and the mechanisms of the reactions
catalyzed:

(1) Various protein studies related to the strtucture, size,

shape, and physicochemical properties of the enzymes.
the organic reaction models for enzyme action^.

(2) Studies on

(3) Kinetic methods.

Enzyme kinetics deals with the measurement of reaction rates and
the derivation of kinetic constants for enzyme systems.

Special kinetic

techniques like continuous flow methods, stopped flow methods, relaxa
tion methods and temperature jump measurements can give very useful in
formation about the enzymic catalysis in some c a s e s H o w e v e r ,
types of more usual kinetic approaches^ are as follows:
velocity studies.
studies.

(2)

Inhibition studies.

(1) Initial

(3) Isotopic exchange

(4) Variation of kinetic parameters with pH.

linear reciprocal plots.

the

(5) Use of non

(6 ) Use of inorganic cations.

Is. Bernhard, "The Structure and Function of Enzymes", W. A.
Benjamin, Inc., Menlo Park, Calif., 1968.
^W. W. Cleland, In: The Enzymes. (Boyer, P. D . , Vol. II, Third
Ed.) 1970, Acad. Press, N. Y . , pp. 1-61.
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I.

INITIAL VELOCITY STUDIES

A determination of initial velocity patterns usually involves
variation of the concentration of one substrate at different fixed
levels of the other components and in the absence of products.

The

normal method for determining initial velocity pattern is to use separ
ate reaction mixture for each substrate concentration.

But it is pos

sible to determine initial velocities as a function of substrate concen
tration from a single progress curve of the reaction if the equilibrium
constant is high and the products do not inhibit the reaction.
In most simple enzyme systems only one of the reactants is rate
limiting.

However, more complex systems may involve more than one

reactants, substrates, and/or intermediates which may be rate limiting.
Kinetic equations describing such complex systems are tedious mathemati
cal expressions.

Nevertheless, rate equations of all enzyme systems can

be reduced to one single rate equation, universally known as MichaelisMenton equation^.

Following is the derivation and some important

features of Michaelis theory:

Michaelis-Menton Equation
Although it is useful to consider the rate equations of a number
of types of possible mechanisms^, a minimum requirement for devising
mechanisms for consideration is an understanding of the kinetic behavior
of a given mechanism.

In order to illustrate the Michaelis theory, one

may consider the following simple type of enzymic mechanism involving a
single intermediate:

3h . L. Segal, In: The Enzymes, (Boyer, P. D . , Lardy, H. and
Myrback, K . , 2nd Ed., Vol. 1) 1959, Acad. Press, N. Y . , p. 1
'^R. A. Alberty, Advances in Enzymology,

1 (1956).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

96
The mechanism
kg _

.

E + S

ES

P + E

'HkJWhere E, S, ES and P are, respectively, the concentrations of free
enzyme, free substrate, enzyme substrate complex and product and the
k's are rate constants.
Further one may consider the following assumptions about the
mechanism:
substrate

(1) There is actually formation of an intermediate enzymecomplex,

is very very small.

(ES).
(3)

(2)

Constant 'kg' is unidirectional as 'k^'

The concentration of substrate is very high as

compared to that of enzyme, i.e., S>>E.
rapidly from the enzyme.

(4) Products are released

(S) Products bear no effect on the interaction

between enzyme and substrate.

(6) Concentrations of the individual com

ponents represent the molar activities and the latter remain unaltered
with respect to their charges in the system.
not change during reaction.

(7) pH of the system does

(8) Solubilities of the reactants do not

change during the reaction.
Velocity of the reaction "v" at any time must be:
V = kg

(ES)

moreover
d (ES) .
= ki [(E)(5)] - kz(ES) - kg (ES)
dt
or

d (ES)
= kiE(E)(5)] - (kg + kg) (ES)
dt

(1)

at steady state
d (ES)
dt
" u
Therefore, equation 1 can be written as:
kl [(E)(5)] = (kg + kg)

(ES)

(2)
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We have the conservation equation;
(Et) = (B) + (ES)

Where (Et) represents total
enzyme concentration.

(E) = (Et) - (ES)
Substituting this value of (E) into Equation (2),we get:
kl [(Et)(S) - (ES)(S)] = k2 (ES) + k3 (ES)
or

kl

(Et)(S) = k2 (ES) + kg (ES) + ki (ES) (S)

or

kl (Et)(S) = (ES) [k2 + kg + ki(S)]
(ES) = k l (fj:.l (S)____
k2 + kg + ki(S)

Dividing both numerator and deniminator of R.H.S. by k i :
(ES) =

(Et) (S)
k1

(S)

"here "m =
Substituting this value of ES into the original equation for the
reaction velocity:

If 'Vmax' is the maximum velocity and
Vmax - k g (Et)
Then equation (3) becomes:

(S)
" Km + CS)

(4)

This is called the Michaelis and Menton Equation.

According to

this equation, a plot of v vs (S) will result in a hyperbola with an
asymptot parallel to abscissa.
Michaelis-Menton constant.

In this equation

represents the

is not usually identical with the disso

ciation constant of the enzyme-substrate complex, but rather it repre
sents the apparent dynamic dissociation constant under steady state
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conditions.

The Michaelis-Menton equation can describe the enzyme b e 

havior at all the concentrations of the substrate studied.

Kj^ of a

system may vary for different substrates, temperature, solvent, anci pH,
Km has the same units as the substrate.

On the other hand Vmax ]bas the

units of velocity and can also vary for different substrates, pH and
temperature.

'Vmax' is dependant upon the enzyme concentration in th^.

system, whereas

is independant.

Some Implications of Michaelis-Menton Equation
If

equation

(4) would reduce to:

V = Vmax

which means that 'v' is the maximum velocity obtainable for a given
enzyme concentration.

Under these conditions, the velocity remains un

changed for any increase in substrate concentration.
called zero order kinetics.

This situation is

If (S) is 100 times K^, the deviation is l i .

When CS)<<Km, equation (4) becomes:
V . ÏSSïja = Vpx

*Mn

= Constant (S)

&m

This equation shows that velocity *v' of the reaction is directly
proportional to substrate concentration (S).
designated as of 'first order' kinetics.

Therefore, reaction may be

If (S) = 0.01 Km, the deviation

from first order is 1%; if (S) = 0 . 1 K^, the deviation from first order
is 9%.
Reaction rate is considered to be of mixed order for any concen
tration of substrate between 0.1

and 10

and is described by

equation (4).
When CS) = K^; equation (4) becomes:

V = 1/2 Vmax
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V max

y
V

/
/

^ ^max

CS)
K
Figure 19.--Effect of substrate concentration on
the rate of an enzyme-catalyzed reaction.
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which means '

equals the concentration of the substrate at which the

reaction velocity equals half the maximum velocity obtainable.

Linear Transformations of Michaelis Equation
(1) Hyperbolic plot (Fig. 19) of v vs (S) is an inaccurate, in
convenient and cumbersome graphical method of determining the kinetic
parameters, Vmax and

(2) High concentrations of substrate must be

used in order to obtain Vmaxî such high concentrations may not be attain
able due to low solubility of substrate and furthermore substrate inhi
bition may occur.
In an effort to overcome these difficulties, various linear
transformations of the Michaelis-Menton equation have been developed.
These may be as follows:
Lineweaver Burk Plot^.

Inverting equation (4) yields;

This is an equation of a straight line with slope Km/Vmax
of ordinate, l/V^ax*

A plot of 1/v vs 1/S (Fig. 20) is helpful in deter

mining Vmax and Km conveniently.
inhibition studies.

intercept

It is also informative for enzyme

But this plot is fairly insensitive at high sub

strate concentrations.

However, this problem can be overcome by

plotting 1/v vs log

.

Eadie Hofstee Plot^.

Dividing both the numerator and denominator

of R.H.S. of equation (4), by (S) yields:

^H. Lineweaver and D. Burk, J. Amer. Chem. Soc.,

658

6g , s . Eadie, J. Biol. Chem., 146, 85 (1942).
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Slope= -Kjn
V

0

V/(S]

Vmax/Km

Figure 2 L — Eadie Hofstee Plot
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(S)/V

G

(S)

Figure 2 2 --Woolf Plot
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V = .■■..Ymax
1 + Km
CS)

I)

or

V + V -7#:r = Vmax

or

V = Vmax -

' Km

(6)

According to this equation a plot of v vs v/(S) results in a straight
line with the slope equal to -Km, the intercept on v/(S) axis equal to
Vmax/Km and the intercept on v axis equal to Vmax

(Fig. 21).

This plot

gives a more even distribution of the experimental points and the two
constants appear separately.

Therefore, any nonlinearity not shown by

Lineweaver-Burk plot becomes apparent.
Woolf Plot?.

Another linear transformation of equation (4) can

be obtained by multiplying both sides of equation (5) by (S):
=
V

& L_ +

Vmax

1__ (S)

Vmax

According to this equation a plot of (S)/v vs (S) gives a straight line
with the slope equal to 1/Vmax> intercept on (S)/v axis equal to Km/Vmax
and the intercept on the (S) axis equal to -Km (Fig. 22).

II.

INHIBITION STUDIES

The significance of inhibition studies has already been discus
sed.

It has now been realized that rarely a kinetic mechanism can be

worked out without extensive resort to inhibition experiments^.

A com

pound that slows down the rate of an enzyme catalyzed reaction is called

7h . Christensen and H, Palmer, "Enzyme Kinetics", W. B. Saunders
C o . , Philadelphia, 1967, p. 103.
% . W. Cleland, In: The Enzymes, (Boyer, P. D . , Vol.
Ed.) 1970, Acad. Press, N. Y . , pp. 1-61.

II, Third
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an inhibitor.

Inhibitors usually form complexes with various enzyme

forms and thus lower the amount of enzyme available for participation in
the normal reaction sequence.

However, inhibitors can also inhibit by

complexing with a substrate , coenzyme or some other component on the
system.

It is possible that the substrate or products may be inhibitory

and thus act as the inhibitors for some form of the enzyme.

When a

molecule which neither acts as a substrate nor as a product but forms
complexes with one or more enzyme forms, is called a dead-end inhibitor.
Inhibitory effect on the enzymic catalysis may also be exerted by an
alternate substrate or an alternate product which may act as inhibitors.
Dénaturation of an enzyme by general protein dénaturants is usually not
considered as inhibition at all, but rather as protein destruction.
Most of the nonallosteric enzyme inhibitions involving enzymeinhibitor interaction can be broadly classified into irreversible or
reversible types.

Irreversible inhibition usually involves the destruc

tion or modification of one or more functional groups of the enzyme.

An

irreversible inhibitor may or may not contain structural elements of the
substrate.

If the catalytic course of an enzyme reaction involves the

formation of metastable covalent enzyme-substrate intermediate, other
molecules which have the ability to form similar but stable covalent
enzymes compounds will function as irreversible inhibitors.

Reversible

inhibition on the other hand can be competitive, uncompetitive, noncom
petitive, or even mixed types.

In the competitive type, the presence of

the inhibitor prevents the access of substrate to the catalytic site and
the El complex is dissociable.

Therefore, competitive inhibition can be

reversed by increasing the substrate concentration.

In the uncompetitive

type of inhibition, the presence of the inhibitor at the catalytic site
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does not necessarily exclude the substrate, but the inhibitor prevents
chemical catalytic action by the enzyme.
in this case.

El complex is dissociable even

The special case of uncompetitive inhibition in which the

presence of the inhibitor has no effect on the binding of the substrate
to the catalytic site, is known as noncompetitive inhibition.
Distinction between these mechanisms can

easily

be made by using

Lineweaver-Burk plots, i.e., plots of 1/v vs 1/S at varying concentra
tions of inhibitor.

If only the slope varies with inhibitor concentra

tion, competitive inhibition is present.
one has uncompetitive inhibition.

If only the intercept varies,

The case in which both slope and

intercepts are function of inhibitor concentrations is termed noncompet
itive

inhibition.

In truly competitive inhibition, double reciprocal

plots are characterized by straight lines of differing slope intercept
ing at a common intercept on the 1/v axis.
itive inhibitor Vmax is not altered but %

In the presence of a compet
is increased.

In noncompet

itive inhibition, the plots differ in slope but do not share a common
intercept on the 1/v axis.
unchanged in this case.

Vmax decreases but Km may or may not remain

In the most usual cases the slope or intercept

variation with the inhibitor concentration is a linear function.

In

more complex cases, the slopes or intercepts give replots which are
hyperbolas or parapolas.
Inhibitors that have the potential of interacting with the sub
strate, may affect enzyme action.

Such an inhibitor can affect the rate

of enzyme catalyzed reaction in three ways:

(a) The inhibitor may combine

with the substrate and decrease its effective concentration,

(b) The in

hibitor may combine with the substrate and the complex formed may act as
an inhibitor for the enzyme.

(c) A combination of the above two mech

anisms .
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These types of inhibitions are frequently difficult to distin
guish from those where apoenzyme is attacked, if the usual kinetic
analysis is applied uncritically.

The most common graphical methods

used to distinguish such inhibitory mechanisms have been described by
Webb^ and ReinerlO in detail.

Among these methods plot of fractional

inhibition (i) against the inhibitor concentration (I), and plots of
I vs i/(l-i) seem to be the most important graphical techniques.

^J. L. Webb, "Enzyme and Metabolic Inhibitors", Vol.
Press, London, 1963, p. 85.

1, Acad.

lOj. M. Reiner, "Behavior of Enzyme Systems", 2nd Ed., Van
Nostrand Reinhold Co., N .Y., 1969, pp. 192-199.
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